CCR7 expression and memory T cell diversity in humans
Campbell, J. J., Murphy, K. E., Kunkel, E. J., Brightling, C. E., Soler, D., Shen, Z. M., … Wu, L. J. (2001). CCR7 expression and memory T cell diversity in humans. JOURNAL OF IMMUNOLOGY, 166(2), 877–84.

Current management of rheumatoid arthritis
Genovese, M. C., & Davis, J. S. (2001). Current management of rheumatoid arthritis. HOSPITAL PRACTICE, 36(2), 21-?

Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential
Kim, C. H., Kunkel, E. J., Boisvert, J., Johnston, B., Campbell, J. J., Genovese, M. C., … BUTCHER, E. C. (2001). Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. JOURNAL OF CLINICAL INVESTIGATION, 107(5), 595–601.

Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival
Uhrin, Z., Wang, B. W. E., Matsuda, Y., Strober, S., & Genovese, M. C. (2001). Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival. ARTHRITIS AND RHEUMATISM, 44(7), 1525–28.

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
Robinson, W. H., Genovese, M. C., & Moreland, L. W. (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? ARTHRITIS AND RHEUMATISM, 44(9), 1977–1983.

Rules of chemokine receptor association with T cell polarization in vivo
Kim, C. H., Rott, L., Kunkel, E. J., Genovese, M. C., Andrew, D. P., Wu, L. J., & BUTCHER, E. C. (2001). Rules of chemokine receptor association with T cell polarization in vivo. JOURNAL OF CLINICAL INVESTIGATION, 108(9), 1331–39.

Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes
Kunkel, E. J., Boisvert, J., Murphy, K., Vierra, M. A., Genovese, M. C., Wardlaw, A. J., … Campbell, J. J. (2002). Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. AMERICAN JOURNAL OF PATHOLOGY, 160(1), 347–55.

Autoantigen microarrays for multiplex characterization of autoantibody responses
Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., KAMACHI, M., Dean, E. J., … Utz, P. J. (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. NATURE MEDICINE, 8(3), 295–301.

Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis
Genovese, M. C., Uhrin, Z., Bloch, D. A., Oehlert, J., Sibley, R. K., Myers, B., & Strober, S. (2002). Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. ARTHRITIS AND RHEUMATISM, 46(4), 1014–18.

Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes
Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., … Finck, B. K. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes. ARTHRITIS AND RHEUMATISM, 46(6), 1443–50.

Central nervous system lupus and pregnancy: 11-year experience at a single center.
El-Sayed, Y. Y., Lu, E. J., Genovese, M. C., Lambert, R. E., Chitkara, U., & Druzin, M. L. (2002). Central nervous system lupus and pregnancy: 11-year experience at a single center. Journal of Maternal-Fetal & Neonatal Medicine , 12(2), 99–103.

COX-2 selective NSAID decreases bone ingrowth in vivo
Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., Wong, N., … Smith, R. L. (2002). COX-2 selective NSAID decreases bone ingrowth in vivo. JOURNAL OF ORTHOPAEDIC RESEARCH, 20(6), 1164–69.

Rheumatic syndromes associated with malignancy
Chakravarty, E., & Genovese, M. C. (2003). Rheumatic syndromes associated with malignancy. CURRENT OPINION IN RHEUMATOLOGY, 15(1), 35–43.

Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase 1 trial
Kavanaugh, A., Genovese, M., Baughman, J., Kivitz, A., Bulpitt, K., Olsen, N., … Mocci, S. (2003). Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase 1 trial. JOURNAL OF RHEUMATOLOGY, 30(3), 449–54.

Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles.
Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., Ikenou, T., … Smith, R. L. (2003). Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. Journal of Biomedical Materials Research. Part A, 65(1), 43–50.

Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging
Yoshioka, H., Alley, M., Steines, D., Stevens, K., Rubesova, E., Genovese, M., … Lang, P. (2003). Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging. JOURNAL OF MAGNETIC RESONANCE IMAGING, 18(1), 66–71.

COX-2 selective inhibitors and bone
Goodman, S. B., Ma, T., Genovese, M., & Smith, R. L. (2003). COX-2 selective inhibitors and bone. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 16(3), 201–5.

Interleukin 1 receptor antagonist inhibits localized bone formation in vivo
Ma, T., Miyanishi, K., Trindade, M. C. D., Genovese, M., Regula, D., Smith, R. L., & Goodman, S. B. (2003). Interleukin 1 receptor antagonist inhibits localized bone formation in vivo. JOURNAL OF RHEUMATOLOGY, 30(12), 2547–52.

A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626].
Genovese, M. C., Chakravarty, E. F., Krishnan, E., & Moreland, L. W. (2004). A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Research & Therapy, 6(1), R73–R77.

Unlocking the "PAD" lock on rheumatoid arthritis
Utz, P. J., Genovese, M. C., & Robinson, W. H. (2004). Unlocking the "PAD" lock on rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 63(4), 330–32.

Articular cartilage of knee: Normal patterns at MR imaging that mimic disease in healthy subjects and patients with osteoarthritis
Yoshioka, H., Stevens, K., Genovese, M., Dillingham, M. F., & Lang, P. (2004). Articular cartilage of knee: Normal patterns at MR imaging that mimic disease in healthy subjects and patients with osteoarthritis. RADIOLOGY, 231(1), 31–38.

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., & Bekker, P. (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. ARTHRITIS AND RHEUMATISM, 50(5), 1412–19.

Associations between rheumatoid arthritis and malignancy
Chakravarty, E. F., & Genovese, M. C. (2004). Associations between rheumatoid arthritis and malignancy. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 271-?

Treatment of rheumatoid arthritis with etanercept
Genovese, M. C., & Kremer, J. M. (2004). Treatment of rheumatoid arthritis with etanercept. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 311-?

Magnetic resonance imaging of articular cartilage of the knee: Comparison between fat-suppressed three-dimensional SPGR imaging, fat-suppressed FSE imaging, and fat-suppressed three-dimensional DEFT imaging, and correlation with arthroscopy
Yoshioka, H., Stevens, K., Hargreaves, B. A., Steines, D., Genovese, M., Dillingham, M. F., … Lang, P. (2004). Magnetic resonance imaging of articular cartilage of the knee: Comparison between fat-suppressed three-dimensional SPGR imaging, fat-suppressed FSE imaging, and fat-suppressed three-dimensional DEFT imaging, and correlation with arthroscopy. JOURNAL OF MAGNETIC RESONANCE IMAGING, 20(5), 857–64.

Pharmacologic modulation of periprosthetic osteolysis
Goodman, S. B., Trindade, M., Ma, T., Genovese, M., & Smith, R. L. (2005). Pharmacologic modulation of periprosthetic osteolysis. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, (430), 39–45.

Temporal effects of a COX-2-selective NSAID on bone ingrowth.
Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., & Smith, R. L. (2005). Temporal effects of a COX-2-selective NSAID on bone ingrowth. Journal of Biomedical Materials Research. Part A, 72(3), 279–87.

Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus
Chakravarty, E. F., Colon, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., Genovese, M. C., & Druzin, M. L. (2005). Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 192(6), 1897–1904.

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
Genovese, M. C., Bathon, J. M., Fleischmann, R. M., Moreland, L. W., Martin, R. W., Whitmore, J. B., … Leff, J. A. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. JOURNAL OF RHEUMATOLOGY, 32(7), 1232–42.

Antigen microarray profiling of autoantibodies in rheumatoid arthritis
Hueber, W., Kidd, B. A., Tomooka, B. H., Lee, B. J., Bruce, B., Fries, J. F., … Robinson, W. H. (2005). Antigen microarray profiling of autoantibodies in rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), 2645–55.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
Genovese, M. C., Becker, J., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., … Dougados, M. (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. NEW ENGLAND JOURNAL OF MEDICINE, 353(11), 1114–23.

Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.
Magnano, M. D., & Genovese, M. C. (2005). Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Current Rheumatology Reports, 7(5), 407–15.

A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis
Genovese, M. C., Chakravarty, E. F., Boyle, D. L., Tutuncu, Z., Thorburn, C. M., Halilhodzic, M., … Kavanaugh, A. (2005). A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. JOURNAL OF RHEUMATOLOGY, 32(12), 2345–50.

Biologic therapies in clinical development for the treatment of rheumatoid arthritis
Genovese, M. C. (2005). Biologic therapies in clinical development for the treatment of rheumatoid arthritis. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 11(3), S45–S54.

Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines
Hueber, W., Tomooka, B. H., Zhao, X., Kidd, B. A., Drijfhout, J. W., Fries, J. F., … Robinson, W. H. (2007). Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. ANNALS OF THE RHEUMATIC DISEASES, 66(6), 712–19.

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., … Robinson, W. H. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. JOURNAL OF CLINICAL INVESTIGATION, 116(10), 2633–42.

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
Genovese, M. C., Mease, P. J., Thomson, G. T. D., Kivitz, A. J., Perdok, R. J., Weinberg, M. A., … Sasso, E. H. (2007). Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. JOURNAL OF RHEUMATOLOGY, 34(5), 1040–50.

A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., Hillygus, J., & Genovese, M. C. (2007). A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. JOURNAL OF RHEUMATOLOGY, 34(6), 1323–27.

A pilot trial of rituximab in the treatment of patients with dermatomyositis
Chung, L., Genovese, M. C., & Fiorentino, D. F. (2007). A pilot trial of rituximab in the treatment of patients with dermatomyositis. ARCHIVES OF DERMATOLOGY, 143(6), 763–67.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., … Dougados, M. (2008). Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. ANNALS OF THE RHEUMATIC DISEASES, 67(4), 547–54.

Efficacy results from pivotal clinical trials with abatacept
Rozelle, A. L., & Genovese, M. C. (2007). Efficacy results from pivotal clinical trials with abatacept. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25(5), S30–S34.

Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo.
Ma, T., Ren, P., Larsen, D. M., Suenaga, E., Zilber, S., Genovese, M., … Goodman, S. B. (2009). Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. Journal of Biomedical Materials Research. Part A, 89(1), 117–23.

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Del Giudice, J., Baldassare, A., Schechtman, J., … Dummer, W. (2008). Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. ARTHRITIS AND RHEUMATISM, 58(9), 2652–61.

Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., … Gomez-Rein, J. J. (2008). Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. ARTHRITIS AND RHEUMATISM, 58(10), 2968–80.

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S., Keystone, E., Matteson, E. L., … Shaw, T. M. (2009). Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. ANNALS OF THE RHEUMATIC DISEASES, 68(12), 1894–97.

Inhibition of p38: Has the Fat Lady Sung
Genovese, M. C. (2009). Inhibition of p38: Has the Fat Lady Sung. ARTHRITIS AND RHEUMATISM, 60(2), 317–320.

Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
Emery, P., Genovese, M. C., van Vollenhoven, R., Sharp, J. T., Patra, K., & Sasso, E. H. (2009). Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 36(7), 1429–1441.

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., Tibshirani, R. J., … Robinson, W. H. (2009). Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY, 11(3).

First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy
Schmajuk, G., & Genovese, M. C. (2009). First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. JOURNAL OF RHEUMATOLOGY, 36(7), 1559–1560.

LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
Genovese, M. C., Van den Bosch, F., ROBERSON, S. A., Bojin, S., Biagini, I. M., Ryan, P., & Sloan-Lancaster, J. (2010). LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study. ARTHRITIS AND RHEUMATISM, 62(4), 929–39.

Abatacept in the Treatment of Patients With Psoriatic Arthritis
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., … Gladman, D. (2011). Abatacept in the Treatment of Patients With Psoriatic Arthritis. ARTHRITIS AND RHEUMATISM, 63(4), 939–948.

An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents
Genovese, M. C., Kavanaugh, A., Weinblatt, M. E., Peterfy, C., DiCarlo, J., White, M. L., … Magilavy, D. B. (2011). An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents. ARTHRITIS AND RHEUMATISM, 63(2), 337–45.

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
Genovese, M. C., Cohen, S. B., Wofsy, D., Weinblatt, M. E., Firestein, G. S., Brahn, E., … Tong, S. E. (2011). A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 38(5), 846–54.

Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial
Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Rossi, C. P., & Tak, P. P. (2011). Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial. ARTHRITIS AND RHEUMATISM, 63(7), 1793–1803.

Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
Genovese, M. C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., Valente, R., … Alten, R. (2011). Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate. ARTHRITIS AND RHEUMATISM, 63(10), 2854–64.

Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study
Genovese, M. C., Han, C., Keystone, E. C., Hsia, E. C., Buchanan, J., Gathany, T., … Rahman, M. U. (2012). Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. JOURNAL OF RHEUMATOLOGY, 39(6), 1185–91.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Mazurov, V., … Mpofu, S. (2013). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals of the Rheumatic Diseases, 72(6), 863–69.

Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Aranda, R., Elegbe, A., & DougadoS, M. (2012). Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. JOURNAL OF RHEUMATOLOGY, 39(8), 1546–54.

Effects of sclerostin antibody on healing of a non-critical size femoral bone defect
Jawad, M. U., Fritton, K. E., Ma, T., Ren, P.-G., Goodman, S. B., Ke, H. Z., … Genovese, M. C. (2013). Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. JOURNAL OF ORTHOPAEDIC RESEARCH, 31(1), 155–63.

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
Genovese, M. C., Fleischmann, R. M., Greenwald, M., Satterwhite, J., Veenhuizen, M., Xie, L., … Benichou, O. (2013). Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. ANNALS OF THE RHEUMATIC DISEASES, 72(9), 1461–68.

Novel small molecule therapeutics in rheumatoid arthritis
Kelly, V., & Genovese, M. (2013). Novel small molecule therapeutics in rheumatoid arthritis. RHEUMATOLOGY, 52(7), 1155–62.

Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial
Genovese, M. C., Bojin, S., Biagini, I. M., Mociran, E., Cristei, D., Mirea, G., … Sloan-Lancaster, J. (2013). Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial. ARTHRITIS AND RHEUMATISM, 65(4), 880–889.

Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2013). Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. JOURNAL OF RHEUMATOLOGY, 40(4), 369–378.

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Genovese, M. C., Rubbert-Roth, A., Smolen, J. S., Kremer, J., Khraishi, M., Gomez-Reino, J., … van Vollenhoven, R. (2013). Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. JOURNAL OF RHEUMATOLOGY, 40(6), 768–80.

Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Stohl, W., Merrill, J. T., McKay, J. D., Lisse, J. R., Zhong, Z. J., Freimuth, W. W., & Genovese, M. C. (2013). Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. JOURNAL OF RHEUMATOLOGY, 40(5), 579–589.

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Genovese, M. C., Lee, E., Satterwhite, J., Veenhuizen, M., Disch, D., Berclaz, P.-Y., … Benichou, O. (2013). A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. ANNALS OF THE RHEUMATIC DISEASES, 72(9), 1453–60.

Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension
Keystone, E. C., Genovese, M. C., Hall, S., Miranda, P. C., Bae, S.-C., Palmer, W., … Hsia, E. C. (2013). Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension. JOURNAL OF RHEUMATOLOGY, 40(7), 1097–1103.

Lemierre's syndrome
Lee, B. K., LOPEZ, F., Genovese, M., & Loutit, J. S. (1997). Lemierre's syndrome. SOUTHERN MEDICAL JOURNAL, 90(6), 640–43.

Fever, rash, and arthritis in a woman with silicone gel breast implants
Genovese, M. C. (1997). Fever, rash, and arthritis in a woman with silicone gel breast implants. WESTERN JOURNAL OF MEDICINE, 167(3), 149–158.

Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment
Genovese, M. C. (1998). Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment. POSTGRADUATE MEDICINE, 103(2), 125-?

Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab
Breedveld, F. C., Khraishi, M. M., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., … Cooper, S. (2007). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. JOURNAL OF RHEUMATOLOGY, 34(7), 1602–1602.

Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab
Breedveld, F. C., Van Vollenhoven, R. F., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., … Cooper, S. (2006). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. TAYLOR & FRANCIS AS.

Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab
Breedveld, F. C., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., Matteson, E. L., … Cooper, S. (2006). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. Presented at the Annual European Congress of Rheumatology (EULAR 2006), AMSTERDAM,NETHERLANDS: BMJ PUBLISHING GROUP.

Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs.
Strand, V., Kremer, J. M., Li, Z. G., Hall, S., Fleischmann, R. M., Genovese, M. C., … Bradley, J. D. (2011). Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs. ARTHRITIS AND RHEUMATISM, 63(10), S1032–S1032.

A randomized, blinded, parallel group, placebo-controlled, pilot study evaluating the effect of Pvac treatment in patients with diffuse systemic sclerosis
Genovese, M. C., Boyle, D., Chakravarty, E., Tutuncu, Z., Thorburn, C., Halilhodzic, M., … Kavanaugh, A. (2004). A randomized, blinded, parallel group, placebo-controlled, pilot study evaluating the effect of Pvac treatment in patients with diffuse systemic sclerosis. ARTHRITIS AND RHEUMATISM, 50(9), S636–S636.

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
Genovese, M. C., Keystone, E., Taylor, P., Drescher, E., Berclaz, P.-Y., Lee, C. H., … Macias, W. (2012). 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S1049–S1050.

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
Peterfy, C. G., Emery, P., Genovese, M. C., Keystone, E., Taylor, P., Berclaz, P.-Y., … Macias, W. (2012). Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S1050–S1051.

12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Smolen, J. S., Schlichting, D. E., Sterling, K. L., Keystone, E., Taylor, P., Genovese, M. C., … Gaich, C. L. (2012). 12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S214–S214.

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Taylor, P., Genovese, M., Keystone, E. C., Drescher, E., Berclaz, P.-Y., Lee, C., … Macias, W. (2013). 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Presented at the Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology, BIRMINGHAM,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS.

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
Schiff, M., Pritchard, C., Huffstutter, J. E., Rodriguez-Valverde, V., Durez, P., Zhou, X., … Genovese, M. C. (2009). The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. ANNALS OF THE RHEUMATIC DISEASES, 68(11), 1708–1714.

Synovial proteome microarrays identify deiminated proteins as targets of the autoantibody response in Rheumatoid Arthritis
Hueber, W., Lee, B. J., Genovese, M. C., Bruce, B., van Venrooij, W. J., Smolen, J. S., … Robinson, W. H. (2003). Synovial proteome microarrays identify deiminated proteins as targets of the autoantibody response in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 48(9), S429–S429.

Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis
Hueber, W., Lee, B. J., Genovese, M., van Venrooij, W., Steinman, L., Utz, P. J., & Robinson, W. H. (2003). Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis. Presented at the 3rd World Congress of the Global-Arthritis-Research-Network (GARN), Miyakazi,JAPAN: BIOMED CENTRAL LTD.

Arthritis antigen microarray analysis reveals associations of distinct autoantibody profiles with markers of disease activity and severity in RA.
Hueber, W., Kidd, B., Lee, B. J., Genovese, M., Bruce, B., Fries, J., … Robinson, W. H. (2004). Arthritis antigen microarray analysis reveals associations of distinct autoantibody profiles with markers of disease activity and severity in RA. ARTHRITIS AND RHEUMATISM, 50(9), S651–S651.

Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis.
Ho, P. P., Tomooka, B. H., Higgins, J. P., Lee, L. Y., Genovese, M., & Robinson, W. H. (2005). Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis. Presented at the 5th Annual Meeting of the Federation-of-Clinical-Immunology-Societies, BOSTON,MA,MA: ACADEMIC PRESS INC ELSEVIER SCIENCE.

Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex)
Emery, P., Keystone, E., Peterfy, C. G., Tak, P.-P., Cohen, S. B., Genovese, M. C., … Shaw, T. M. (2008). Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex). Presented at the Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology, LIVERPOOL,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS.

Dehydroepiandrosterone (DHEA) in severe systemic lupus erythematosus. Results of a double-blinded, placebo controlled pilot study.
Genovese, M. C., Hendrickson, C. L., Park, J., Powell, M. J., McGuire, J. L., & VANVOLLENHOVEN, R. F. (1997). Dehydroepiandrosterone (DHEA) in severe systemic lupus erythematosus. Results of a double-blinded, placebo controlled pilot study. ARTHRITIS AND RHEUMATISM, 40(9), 168–68.

The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial.
Genovese, M., Luggen, M., Kremer, J., Sany, J., Aranda, R., Becker, J. C., … Dougados, M. (2005). The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial. ARTHRITIS AND RHEUMATISM, 52(9), S137–S137.

Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIN trial.
Dougados, M., Kavanagh, A., Espinoza, L., Sibilia, J., Aranda, R., Becker, J. C., … Luggen, M. (2005). Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIN trial. ARTHRITIS AND RHEUMATISM, 52(9), S137–S138.

Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial
Dougados, M., Schiff, M., Luggen, M., Becker, J. C., Aranda, R., Li, T., … Genovese, M. C. (2007). Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial. Presented at the Annual Meeting of the British-Society-of-Rheumatology, BIRMINGHAM,ENGLAND,ENGLAND: OXFORD UNIV PRESS.

SAFETY, EFFICACY AND HEALTH-RELATED QUALITY OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS FACTOR THERAPY
Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Becker, J.-C., Aranda, R., … DougadoS, M. (2011). SAFETY, EFFICACY AND HEALTH-RELATED QUALITY OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS FACTOR THERAPY. Presented at the Annual Meeting of the British-Society-for-Rheumatology 2011, BRIGHTON,ENGLAND: OXFORD UNIV PRESS.

CTLA4IG (BMS-188667) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers
Schiff, M., Genovese, M., Nuamah, I., Becker, J., & Weinblatt, M. (2003). CTLA4IG (BMS-188667) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers. Presented at the Annual European Congress of Rheumatology, LISBON,PORTUGAL: BMJ PUBLISHING GROUP.

Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial.
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., McCann, T., … Dougados, M. (2006). Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. ARTHRITIS AND RHEUMATISM, 54(9), S244–S244.

Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders)
Genovese, M., Luggen, M., Schiff, M., Sherrer, Y., Nuamah, I., Aranda, R., … Dougados, M. (2004). Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders). ARTHRITIS AND RHEUMATISM, 50(12), 4103–4103.

Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation.
Genovese, M., Schiff, M., Luggen, M., Aranda, R., Becker, J. C., White, A., & Dougados, M. (2005). Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation. ARTHRITIS AND RHEUMATISM, 52(9), S560–S561.

Beneficial effects of the selective CO-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment
Emery, R., Westhovens, R., LEON, G., Nuamah, I., Ge, Z., Aranda, R., … Dougados, M. (2005). Beneficial effects of the selective CO-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment. Presented at the Annual European Congress of Rheumatology, VIENNA,AUSTRIA: BMJ PUBLISHING GROUP.

Abatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the attain trial
Schiff, M., Dougados, M., Luggen, M., Espinoza, L., Nuamah, I., Aranda, R., … Genovese, M. (2005). Abatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the attain trial. Presented at the Annual European Congress of Rheumatology, VIENNA,AUSTRIA: BMJ PUBLISHING GROUP.

Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data.
Genovese, M. C., Hochberg, M. C., Cohen, R. B., Weinblatt, M. E., Kaine, J., Keystone, E., … Alten, R. (2012). Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data. ARTHRITIS AND RHEUMATISM, 64(10), S725–S725.

Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to MethotrexatE) Trial.
Genovese, M. C., Covarrubias Cobos, A., Leon, G., Mysler, E. F., Keiserman, M. W., Valente, R. M., … Alten, R. (2011). Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to MethotrexatE) Trial. ARTHRITIS AND RHEUMATISM, 63(10), S150–S150.

WEEKLY SUBCUTANEOUS ABATACEPT CONFERS COMPARABLE ONSET OF TREATMENT RESPONSE AND MAGNITUDE OF EFFICACY IMPROVEMENT OVER 6 MONTHS WHEN ADMINISTERED WITH OR WITHOUT AN INTRAVENOUS ABATACEPT LOADING DOSE
Schiff, M., Alten, R., Weinblatt, M. E., Nash, P., Fleischmann, R., Durez, P., … Genovese, M. (2013). WEEKLY SUBCUTANEOUS ABATACEPT CONFERS COMPARABLE ONSET OF TREATMENT RESPONSE AND MAGNITUDE OF EFFICACY IMPROVEMENT OVER 6 MONTHS WHEN ADMINISTERED WITH OR WITHOUT AN INTRAVENOUS ABATACEPT LOADING DOSE. Presented at the Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology, BIRMINGHAM,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS.

Safety Profile of Subcutaneous Abatacept Focusing on Clinically Relevant Events in Patients with Rheumatoid Arthritis (RA) and up to 4.5 Years of Exposure.
Alten, R., Kaine, J. L., Keystone, E., Nash, P. T., Delaet, I., Qi, K., & Genovese, M. C. (2011). Safety Profile of Subcutaneous Abatacept Focusing on Clinically Relevant Events in Patients with Rheumatoid Arthritis (RA) and up to 4.5 Years of Exposure. ARTHRITIS AND RHEUMATISM, 63(10), S150–S151.

Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
Genovese, M. C., Pacheco-Tena, C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., … Alten, R. (2012). Subcutaneous Abatacept: Long-Term Data From the Acquire Trial. ARTHRITIS AND RHEUMATISM, 64(10), S201–S201.

THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) IS CONSISTENT WITH THE ESTABLISHED INTRAVENOUS (IV) PROFILE IN A STUDY OF 1457 PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO MTX (MTX-IR)
Nash, P., Genovese, M., COVARRUBIAS, J., LEON, G., Mysler, E., Keiserman, M., … Bamford, T. (2011). THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) IS CONSISTENT WITH THE ESTABLISHED INTRAVENOUS (IV) PROFILE IN A STUDY OF 1457 PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO MTX (MTX-IR). WILEY-BLACKWELL.

THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) WITH OR WITHOUT MTX IN PATIENTS WITH ACTIVE RA
Nash, P., Nayiager, S., Genovese, M., Rodriguez, C., Delaet, I., Elegbe, A., … Bamford, T. (2011). THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) WITH OR WITHOUT MTX IN PATIENTS WITH ACTIVE RA. WILEY-BLACKWELL.

SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF EXPOSURE
Alten, R., Kaine, J. L., Keystone, E., Nash, P. T., Delaet, I., Qi, K., & Genovese, M. C. (2012). SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF EXPOSURE. Presented at the Annual Meeting of the British-Society-for-Rheumatology, GLASGOW,SCOTLAND: OXFORD UNIV PRESS.

A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naive to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors.
Genovese, M. C., Greenwald, M. W., Cho, C. S., Berman, A., Jin, L., Cameron, G., … Warner, L. (2011). A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naive to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors. ARTHRITIS AND RHEUMATISM, 63(10), S1017–S1017.

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus - Results of a multicenter randomized, double-blind, placebo-controlled trial
Petri, M. A., Mease, P. J., Merrill, J. T., Lahita, R. G., Iannini, M. J., Yocum, D. E., … Schwartz, K. E. (2004). Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus - Results of a multicenter randomized, double-blind, placebo-controlled trial. ARTHRITIS AND RHEUMATISM, 50(9), 2858–68.

IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study
Genovese, M., McKay, J., Nasonov, E., Myster, E., da Silva, N., Alecock, E., … Gomez-Reino, J. (2007). IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study. ARTHRITIS AND RHEUMATISM, 56(12), 4309–4310.

RAPID AND SIGNIFICANT REDUCTION OF DAS28 FOLLOWING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Smolen, J. S., Mysler, E. F., Rubbert-Roth, A., Gomez-Reino, J., Alten, R., Law, A., … Genovese, M. (2009). RAPID AND SIGNIFICANT REDUCTION OF DAS28 FOLLOWING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Presented at the Annual Meeting of the British-Society-of-Rheumatology, GLASGOW,SCOTLAND: OXFORD UNIV PRESS.

RAPID AND SIGNIFICANT REDUCTION IN DISEASE ACTIVITY WITH TOCILIZUMAB IN COMBINATION WITH SIX DIFFERENT DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: THE TOWARD STUDY
Gomez-Reino, J. J., Nasonov, E. L., McKay, J. D., Mysler, E. F., da Silva, N., Alecock, E., … Genovese, M. C. (2009). RAPID AND SIGNIFICANT REDUCTION IN DISEASE ACTIVITY WITH TOCILIZUMAB IN COMBINATION WITH SIX DIFFERENT DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: THE TOWARD STUDY. Presented at the Annual Meeting of the British-Society-of-Rheumatology, GLASGOW,SCOTLAND: OXFORD UNIV PRESS.

Quality of life and functional improvements with the IL-6 receptor inhibitor tocilizumab in patients with active rheumatoid arthritis despite DMARD therapy: The toward study
Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Laughton, J., … Genovese, M. C. (2008). Quality of life and functional improvements with the IL-6 receptor inhibitor tocilizumab in patients with active rheumatoid arthritis despite DMARD therapy: The toward study. Presented at the Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology, LIVERPOOL,ENGLAND: OXFORD UNIV PRESS.

IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study
Genovese, M., Brown, J. P., McKay, J., Nasonov, E., Mysler, E., da Silva, N., … Gomez-Reino, J. (2008). IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study. JOURNAL OF RHEUMATOLOGY. MT TREMBLANT,CANADA,CANADA: J RHEUMATOL PUBL CO.

Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs
Gomez-Reino, J. J., Nair, B., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., & Genovese, M. (2008). Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs. JOURNAL OF RHEUMATOLOGY, 35(6), 1216–1216.

Targeted inhibition of IL-6 signalling withtocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs
Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., & Genovese, M. (2007). Targeted inhibition of IL-6 signalling withtocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs. ARTHRITIS AND RHEUMATISM, 56(12), 4234–4234.

Combination therapy of leflunomide (LEF) & methotrexate (MTX) is effective & well tolerated in RA patients inadequately responding to MTX alone
Kremer, J. M., Genovese, M., Cannon, G. W., Caldwell, J. R., Cush, J. J., & Bathon, J. (2001). Combination therapy of leflunomide (LEF) & methotrexate (MTX) is effective & well tolerated in RA patients inadequately responding to MTX alone. J RHEUMATOL PUBL CO.

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2010). An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. NEW ENGLAND JOURNAL OF MEDICINE, 363(14), 1303–1312.

Safety and Efficacy of Etanercept Beyond 10 Years of Therapy in North American Patients With Early and Longstanding Rheumatoid Arthritis
Weinblatt, M. E., Bathon, J. M., Kremer, J. M., Fleischmann, R. M., Schiff, M. H., Martin, R. W., … Genovese, M. C. (2011). Safety and Efficacy of Etanercept Beyond 10 Years of Therapy in North American Patients With Early and Longstanding Rheumatoid Arthritis. ARTHRITIS CARE & RESEARCH, 63(3), 373–82.

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial
Kremer, J., Genovese, M., Cannon, G. W., Caldwell, J., Cush, J., Furst, D. E., … Strand, V. (2004). Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. JOURNAL OF RHEUMATOLOGY, 31(8), 1521–1531.

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate - A randomized, double-blind, placebo-controlled trial
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., … Bathon, J. M. (2002). Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate - A randomized, double-blind, placebo-controlled trial. ANNALS OF INTERNAL MEDICINE, 137(9), 726–733.

Running and osteoarthritis of the knee: A 12 year longitudinal study.
Lane, N. E., Oehlert, J., Ward, M., Genovese, M., Bloch, D., & Fries, J. F. (1997). Running and osteoarthritis of the knee: A 12 year longitudinal study. ARTHRITIS AND RHEUMATISM, 40(9), 1242–1242.

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
Robinson, W. H., Paniagua, R. T., Ho, P. P., Chan, S. M., Sharpe, O., Utz, P. J., & Genovese, M. C. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. ARTHRITIS AND RHEUMATISM, 54(9), S356–S357.

A pilot study of TNF inhibition in Erosive/Inflammatory osteoarthritis of the hands.
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., Hillygus, J. J., & Genovese, M. C. (2006). A pilot study of TNF inhibition in Erosive/Inflammatory osteoarthritis of the hands. ARTHRITIS AND RHEUMATISM, 54(9), S674–S674.

IN PATIENTS WITH EARLY RA WHO HAD ACHIEVED A NORMAL CRP, ADALIMUMAB INHIBITED RADIOGRAPHIC PROGRESSION MORE EFFECTIVELY THAN METHOTREXATE
Emery, P., Genovese, M., Van Vollenhoven, R. F., & Sasso, E. H. (2009). IN PATIENTS WITH EARLY RA WHO HAD ACHIEVED A NORMAL CRP, ADALIMUMAB INHIBITED RADIOGRAPHIC PROGRESSION MORE EFFECTIVELY THAN METHOTREXATE. Presented at the Annual Meeting of the British-Society-of-Rheumatology, GLASGOW,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND: OXFORD UNIV PRESS.

Radiographic progression and clinical status are differentially related for adalimumab plus methotrexate (MTX) vs. monotherapy with adalimumab or MTX: Subanalysis of premier
Emery, P., Genovese, M., van Vollenhoven, R., Patra, K., & Sasso, E. (2008). Radiographic progression and clinical status are differentially related for adalimumab plus methotrexate (MTX) vs. monotherapy with adalimumab or MTX: Subanalysis of premier. Presented at the Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology, LIVERPOOL,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS.

Safety of TNF inhibitors (TNF-is) and non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) previously treated with Rituximab (RTX)
Genovese, M., van Vollenhoven, R., Breedveld, F., Emery, P., Moreland, L., Keystone, E., … Shaw, T. (2008). Safety of TNF inhibitors (TNF-is) and non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) previously treated with Rituximab (RTX). INFORMA HEALTHCARE.

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen, K. E., Cush, J. J., Patel, S., Genovese, M. C., & Schiff, M. (2002). The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 46(9), S538–S538.

Golimumab administered subcutaneously every 4 wks in patients with active rheumatoid arthritis despite methotrexate: Wk 24 results of the randomized, double-blind, placebo-controlled, GO-FORWARD study
Keystone, E., Genovese, M. C., Klareskog, L., Hsia, E. C., Livingston, J., Wiekowski, M., … Rahman, M. U. (2008). Golimumab administered subcutaneously every 4 wks in patients with active rheumatoid arthritis despite methotrexate: Wk 24 results of the randomized, double-blind, placebo-controlled, GO-FORWARD study. ARTHRITIS AND RHEUMATISM, 58(9), S618–S619.

Computer-assisted pattern recognition of autoantibody results
Binder, S. R., Genovese, M. C., Merrill, J. T., Morris, R. I., & Metzger, A. L. (2005). Computer-assisted pattern recognition of autoantibody results. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 12(12), 1353–57.

Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., … Rahman, M. U. (2009). Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. ANNALS OF THE RHEUMATIC DISEASES, 68(6), 789–96.

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
Keystone, E., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S., Miranda, P. C., … Rahman, M. U. (2010). Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. ANNALS OF THE RHEUMATIC DISEASES, 69(6), 1129–1135.

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., … Finck, B. K. (2000). A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. NEW ENGLAND JOURNAL OF MEDICINE, 343(22), 1586–1593.

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus
Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., … Serono, M. (2007). Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. ARTHRITIS AND RHEUMATISM, 56(12), 4142–50.

Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
Wasko, M. C., Hsia, E. C., Kirkham, B., Touboul, P.-J., Fleischmann, R., Genovese, M. C., … Rahman, M. U. (2014). Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides. Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, 20(1), 1–10.

Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation
Kirkham, B. W., Wasko, M. C., Hsia, E. C., Fleischmann, R. M., Genovese, M. C., Matteson, E. L., … Rahman, M. U. (2014). Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation. ANNALS OF THE RHEUMATIC DISEASES, 73(1), 161–169.

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., … Mpofu, S. (2014). One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. Journal of Rheumatology, 41(3), 414–21.

Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial.
Genovese, M. C., Tena, C. P., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., … Alten, R. (2014). Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. Journal of Rheumatology, 41(4), 629–39.

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
Emery, P., van der Heijde, D., Ostergaard, M., Conaghan, P. G., Genovese, M. C., Keystone, E. C., … Rahman, M. U. (2011). Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 70(12), 2126–2130.

Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
Visvanathan, S., Rahman, M. U., Keystone, E., Genovese, M., Klareskog, L., Hsia, E., … Wagner, C. (2010). Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. ARTHRITIS RESEARCH & THERAPY, 12(6).

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
Conaghan, P. G., Emery, P., Ostergaard, M., Keystone, E. C., Genovese, M. C., Hsia, E. C., … Rahman, M. U. (2011). Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. ANNALS OF THE RHEUMATIC DISEASES, 70(11), 1968–1974.

The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
Emery, P., Fleischmann, R., van der Heijde, D., Keystone, E. C., Genovese, M. C., Conaghan, P. G., … Rahman, M. U. (2011). The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy. ARTHRITIS AND RHEUMATISM, 63(5), 1200–1210.

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-alpha Antagonist
Genovese, M. C., van der Heijde, D. M., Keystone, E. C., Spindler, A. J., Benhamou, C., Kavanaugh, A., … Weinblatt, M. E. (2014). A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-alpha Antagonist. JOURNAL OF RHEUMATOLOGY, 41(11), 2120–28.

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment
Alten, R., Kaine, J., Keystone, E., Nash, P., Delaet, I., & Genovese, M. C. (2014). Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment. ARTHRITIS & RHEUMATOLOGY, 66(8), 1987–1997.

A randomized, controlled trial of interferon-beta-1a (Avonex (R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]
Genovese, M. C., Chakravarty, E. F., Krishnan, E., & Moreland, L. W. (2004). A randomized, controlled trial of interferon-beta-1a (Avonex (R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. ARTHRITIS RESEARCH & THERAPY, 6(1), R73–R77.

Epitope-Specific Immunotherapy of Rheumatoid Arthritis Clinical Responsiveness Occurs With Immune Deviation and Relies on the Expression of a Cluster of Molecules Associated With T Cell Tolerance in a Double-Blind, Placebo-Controlled, Pilot Phase II Trial
Koffeman, E. C., Genovese, M., Amox, D., Keogh, E., Santana, E., Matteson, E. L., … Albani, S. (2009). Epitope-Specific Immunotherapy of Rheumatoid Arthritis Clinical Responsiveness Occurs With Immune Deviation and Relies on the Expression of a Cluster of Molecules Associated With T Cell Tolerance in a Double-Blind, Placebo-Controlled, Pilot Phase II Trial. ARTHRITIS AND RHEUMATISM, 60(11), 3207–3216.

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
Hansen, K. E., Hildebrand, J. P., Genovese, M. C., Cush, J. J., Patel, S., Cooley, D. A., … Schiff, M. H. (2004). The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. JOURNAL OF RHEUMATOLOGY, 31(6), 1098–1102.

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
Keystone, E., Emery, P., Peterfy, C. G., Tak, P. P., Cohen, S., Genovese, M. C., … Shaw, T. (2009). Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. ANNALS OF THE RHEUMATIC DISEASES, 68(2), 216–21.

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
Cohen, S. B., Keystone, E., Genovese, M. C., Emery, P., Peterfy, C., Tak, P. P., … Hagerty, D. (2010). Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. ANNALS OF THE RHEUMATIC DISEASES, 69(6), 1158–61.

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., CALVO, A., Gomez-Reino, J. J., … Genovese, M. C. (2010). Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. ANNALS OF THE RHEUMATIC DISEASES, 69(1), 88–96.

The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis
Hansen, K. E., Cush, J., Singhal, A., Cooley, D. A., Cohen, S., Patel, S. R., … Schiff, M. (2004). The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 51(2), 228–32.

Demyelination and inhibition of tumor necrosis factor (TNF)
Magnano, M. D., Robinson, W. H., & Genovese, M. C. (2004). Demyelination and inhibition of tumor necrosis factor (TNF). CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 22(5), S134–S140.

Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study
Weinblatt, M. E., Kremer, J., Cush, J., Rigby, W., Teng, L. L., Devenport, J., … Genovese, M. C. (2013). Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study. ARTHRITIS CARE & RESEARCH, 65(3), 362–371.

Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study
Nash, P., Nayiager, S., Genovese, M. C., Kivitz, A. J., Oelke, K., Ludivico, C., … Corbo, M. (2013). Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study. ARTHRITIS CARE & RESEARCH, 65(5), 718–728.

Longitudinal Evaluation of the Occurrence of MRI-Detectable Bone Marrow Edema in Osteoarthritis of the Knee
Brem, M. H., Schlechtweg, P. M., Bhagwat, J., Genovese, M., Dillingham, M. F., Yoshioka, H., & Lang, P. (2008). Longitudinal Evaluation of the Occurrence of MRI-Detectable Bone Marrow Edema in Osteoarthritis of the Knee. ACTA RADIOLOGICA, 49(9), 1031–1037.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Cohen, S. B., Emery, P., Greenwald, M. W., DougadoS, M., Furie, R. A., Genovese, M. C., … Totoritis, M. C. (2006). Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. ARTHRITIS AND RHEUMATISM, 54(9), 2793–2806.

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Genovese, M. C., Fleischmann, R., Furst, D., Janssen, N., Carter, J., Dasgupta, B., … Kretsos, K. (2014). Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. ANNALS OF THE RHEUMATIC DISEASES, 73(9), 1607–15.

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Genovese, M. C., Greenwald, M., Cho, C.-S., Berman, A., Jin, L., Cameron, G. S., … Banerjee, S. (2014). A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors. ARTHRITIS & RHEUMATOLOGY, 66(7), 1693–1704.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell-Bakalarska, M., Martincova, R., Fiore, S., … van der Heijde, D. (2015). Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis & Rheumatology , 67(6), 1424–37.

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
Chakravarty, E. F., Martyanov, V., Fiorentino, D., Wood, T. A., Haddon, D. J., Jarrell, J. A., … Chung, L. (2015). Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Research & Therapy, 17, 159-?

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
Nair, N., Mei, H. E., Chen, S.-Y., Hale, M., Nolan, G. P., Maecker, H. T., … Whiting, C. C. (2015). Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. Arthritis Research & Therapy, 17, 127-?

Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Genovese, M. C., Jarosova, K., Cieslak, D., Alper, J., Kivitz, A., Hough, D. R., … Zaidi, F. (2015). Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. ARTHRITIS & RHEUMATOLOGY, 67(7), 1703–10.

Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis
Moreland, L. W., Genovese, M. C., Sato, R., & Singh, A. (2006). Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 55(2), 287–293.

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Fleischmann, R., Cutolo, M., Genovese, M. C., Lee, E. B., Kanik, K. S., Sadis, S., … Zwillich, S. H. (2012). Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. ARTHRITIS AND RHEUMATISM, 64(3), 617–29.

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial
Tak, P. P., Mease, P. J., Genovese, M. C., Kremer, J., Haraoui, B., Tanaka, Y., … Dummer, W. (2012). Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. ARTHRITIS AND RHEUMATISM, 64(2), 360–70.

Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O)
Genovese, M. C., Silverman, G. J., Emery, P., Gupta, R. C., Gill, A., Veenhuizen, M., … Lee, C. (2015). Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O). JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 21(5), 231–38.

Serum 14-3-3 eta is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
Maksymowych, W. P., Naides, S. J., Bykerk, V., Siminovitch, K. A., van Schaardenburg, D., Boers, M., … Marotta, A. (2014). Serum 14-3-3 eta is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 41(11), 2104–13.

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., … Nirula, A. (2014). Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. NEW ENGLAND JOURNAL OF MEDICINE, 370(24), 2295–2306.

Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies
Schiff, M. H., Yu, E. B., Weinblatt, M. E., Moreland, L. W., Genovese, M. C., White, B., … Woolley, J. M. (2006). Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies. DRUGS & AGING, 23(2), 167–178.

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., … Bradley, J. (2013). Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial. ANNALS OF INTERNAL MEDICINE, 159(4), 253-?

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
van Holten, J., Pavelka, K., Vencovsky, J., Stahl, H., Rozman, B., Genovese, M., … Tak, P. P. (2005). A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 64(1), 64–69.

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Weinblatt, M. E., Genovese, M. C., Ho, M., Hollis, S., Rosiak-Jedrychowicz, K., Kavanaugh, A., … van der Heijde, D. (2014). Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. ARTHRITIS & RHEUMATOLOGY, 66(12), 3255–64.

The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate
Bathon, J. M., & Genovese, M. C. (2003). The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 21(5), S195–S197.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., … Genovese, M. C. (2015). Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. ANNALS OF THE RHEUMATIC DISEASES, 74(2), 333–40.

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy
Nair, N., Mei, H. E., Chen, S.-Y., Hale, M., Nolan, G. P., Maecker, H. T., … Whiting, C. C. (2015). Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. ARTHRITIS RESEARCH & THERAPY, 17.

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis
Chakravarty, E. F., Martyanov, V., Fiorentino, D., Wood, T. A., Haddon, D. J., Jarrell, J. A., … Chung, L. (2015). Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. ARTHRITIS RESEARCH & THERAPY, 17.

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-a antagonist.
Genovese, M. C., van der Heijde, D. M., Keystone, E. C., Spindler, A. J., Benhamou, C., Kavanaugh, A., … Weinblatt, M. E. (2014). A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-a antagonist. Journal of Rheumatology, 41(11), 2120–28.

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Genovese, M. C., Hsia, E., Belkowski, S. M., Chien, C., Masterson, T., Thurmond, R. L., … Greenspan, A. (2015). Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. Journal of Rheumatology, 42(10), 1752–60.

OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
Taylor, P. C., Genovese, M. C., Greenwood, M., Ho, M., Nasonov, E., Oemar, B., … Weinblatt, M. (2015). OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. ANNALS OF THE RHEUMATIC DISEASES, 74(12), 2123–29.

Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis
Wilson, H. D., Mutebi, A., Revicki, D. A., Mease, P. J., Genovese, M. C., Erondu, N., … Viswanathan, H. N. (2015). Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis. ARTHRITIS CARE & RESEARCH, 67(12), 1750–56.

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
Genovese, M. C., Van Vollenhoven, R. F., Pacheco-Tena, C., Zhang, Y., & Kinnman, N. (2016). VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 68(1), 46–55.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study
Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell-Bakalarska, M., Martincova, R., Fiore, S., … van der Heijde, D. (2015). Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study. ARTHRITIS & RHEUMATOLOGY, 67(6), 1424–37.

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
Genovese, M. C., Braun, D. K., Erickson, J. S., Berclaz, P.-Y., Banerjee, S., Heffernan, M. P., & Carlier, H. (2016). Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis. Journal of Rheumatology, 43(2), 289–97.

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis
Burmester, G. R., Durez, P., Shestakova, G., Genovese, M. C., Schulze-Koops, H., Li, Y., … Hueber, W. (2016). Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. RHEUMATOLOGY, 55(1), 49–55.

Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
Keystone, E. C., Genovese, M. C., Hall, S., Bae, S.-C., Han, C., Gathany, T. A., … Hsia, E. C. (2016). Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. Journal of Rheumatology, 43(2), 298–306.

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
Mease, P. J., Genovese, M. C., Mutebi, A., Viswanathan, H. N., Chau, D., Feng, J., … Nirula, A. (2016). Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. Journal of Rheumatology, 43(2), 343–49.

Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials
Wallenstein, G. V., Kanik, K. S., Wilkinson, B., Cohen, S., Cutolo, M., Fleischmann, R., … Zwillich, S. H. (2016). Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 34(3), 430–42.

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
Strand, V., Kosinski, M., Chen, C.-I., Joseph, G., Rendas-Baum, R., Graham, N. M. H., … Genovese, M. C. (2016). Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Research & Therapy, 18, 198-?

Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
Wallenstein, G. V., Kanik, K. S., Wilkinson, B., Cohen, S., Cutolo, M., Fleishmann, R., … Zwillich, S. H. (2016). Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clinical and Experimental Rheumatology, 34(3), 430–42.

Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles
Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., Ikenou, T., … Smith, R. L. (2003). Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 65A(1), 43–50.

Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo
Ma, T., Ren, P.-G., Larsen, D. M., Suenaga, E., Zilber, S., Genovese, M., … Goodman, S. B. (2009). Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 89A(1), 117–23.

Temporal effects of a COX-2-selective NSAID on bone ingrowth
Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., & Smith, R. L. (2005). Temporal effects of a COX-2-selective NSAID on bone ingrowth. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 72A(3), 279–87.

Cutting edge: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues
Pan, J. L., Kunkel, E. J., Gosslar, U., Lazarus, N., Langdon, P., Broadwell, K., … Soler, D. (2000). Cutting edge: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. JOURNAL OF IMMUNOLOGY, 165(6), 2943–49.

Increased pretreatment serum IFN-/ ratio predicts non-response to tumour necrosis factor inhibition in rheumatoid arthritis
Muskardin, T. W., Vashisht, P., Dorschner, J. M., Jensen, M. A., Chrabot, B. S., Kern, M., … Niewold, T. B. (2016). Increased pretreatment serum IFN-/ ratio predicts non-response to tumour necrosis factor inhibition in rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 75(10), 1757–62.

Impact of a positive youth development program in urban after-school settings on the prevention of adolescent substance use
Tebes, J. K., Feinn, R., Vanderploeg, J. J., Chinman, M. J., Shepard, J., Brabham, T., … Connell, C. (2007). Impact of a positive youth development program in urban after-school settings on the prevention of adolescent substance use. JOURNAL OF ADOLESCENT HEALTH, 41(3), 239–47.

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri, M. A., Mease, P. J., Merrill, J. T., Lahita, R. G., Iannini, M. J., Yocum, D. E., … Schwartz, K. E. (2004). Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis and Rheumatism, 50(9), 2858–68.

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Alten, R., Bingham, C. O., Cohen, S. B., Curtis, J. R., Kelly, S., Wong, D., & Genovese, M. C. (2016). Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC MUSCULOSKELETAL DISORDERS, 17.

Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., … Smolen, J. S. (2016). Baricitinib in Patients with Refractory Rheumatoid Arthritis. NEW ENGLAND JOURNAL OF MEDICINE, 374(13), 1243–52.

INCIDENCE OF AND RISK-FACTORS FOR HOSPITALIZATIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE-STUDY OF THE HOPKINS LUPUS COHORT
Petri, M., & Genovese, M. (1992). INCIDENCE OF AND RISK-FACTORS FOR HOSPITALIZATIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE-STUDY OF THE HOPKINS LUPUS COHORT. JOURNAL OF RHEUMATOLOGY, 19(10), 1559–59.

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., … Wofsy, D. (2007). Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis and Rheumatism, 56(12), 4142–50.

Sarilumab, a fully human monoclonal antibody against IL-6R alpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
Huizinga, T. W. J., Fleischmann, R. M., Jasson, M., Radin, A. R., van Adelsberg, J., Fiore, S., … Genovese, M. C. (2014). Sarilumab, a fully human monoclonal antibody against IL-6R alpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. ANNALS OF THE RHEUMATIC DISEASES, 73(9), 1626–34.

DEFINITION, INCIDENCE, AND CLINICAL DESCRIPTION OF FLARE IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE COHORT STUDY
Petri, M., Genovese, M., Engle, E., & Hochberg, M. (1991). DEFINITION, INCIDENCE, AND CLINICAL DESCRIPTION OF FLARE IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE COHORT STUDY. ARTHRITIS AND RHEUMATISM, 34(8), 937–44.

Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.
Genovese, M. C., Yang, F., Østergaard, M., & Kinnman, N. (2016). Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Annals of the Rheumatic Diseases, 75(11), 1979–83.

Prevalence and risk factors for Staphylococcus aureus colonization in individuals entering maximum-security prisons
Mukherjee, D. V., Herzig, C. T. A., Jeon, C. Y., Lee, C. J., Apa, Z. L., Genovese, M., … Larson, E. L. (2014). Prevalence and risk factors for Staphylococcus aureus colonization in individuals entering maximum-security prisons. EPIDEMIOLOGY AND INFECTION, 142(3), 484–93.

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Genovese, M. C., Van Vollenhoven, R. F., Wilkinson, B., Wang, L., Zwillich, S. H., Gruben, D., … Jones, T. V. (2016). Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY, 18.

Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in methotrexate-inadequate responders.
Kivitz, A. J., Gutierrez-Ureña, S. R., Poiley, J., Genovese, M. C., Kristy, R., Shay, K., … Zubrzycka-Sienkiewicz, A. (2016). Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in methotrexate-inadequate responders. Arthritis & Rheumatology .

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
Burmester, G. R., Landew, R., Genovese, M. C., Friedman, A. W., Pfeifer, N. D., Varothai, N. A., & Lacerda, A. P. (2017). Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 76(2), 414–17.

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., … Jungerwirth, S. (2016). Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY, 68(12), 2857–66.

Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures
Yazdany, J., Robbins, M., Schmajuk, G., DeSai, S., Lacaille, D., Neogi, T., … Newman, E. (2016). Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. ARTHRITIS CARE & RESEARCH, 68(11), 1579–90.

Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis.
Genovese, M. C., Greenwald, M., Codding, C., Zubrzycka-Sienkiewicz, A., Kivitz, A. J., Wang, A., … Cardiel, M. H. (2017). Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis & Rheumatology (Hoboken, N.J.).

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
Moots, R. J., Sebba, A., Rigby, W., Ostor, A., Porter-Brown, B., Donaldson, F., … Genovese, M. C. (2016). Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford, England).

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
Moots, R. J., Sebba, A., Rigby, W., Ostor, A., Porter-Brown, B., Donaldson, F., … Genovese, M. C. (2017). Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. RHEUMATOLOGY, 56(4), 541–49.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis
Kremer, J. M., Genovese, M. C., Keystone, E., Taylor, P. C., Zuckerman, S. H., Ruotolo, G., … Macias, W. L. (2017). Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 69(5), 943–52.

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
Burmester, G. R., Choy, E., Kivitz, A., Ogata, A., Bao, M., Nomura, A., … Genovese, M. C. (2017). Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 76(6), 1078–85.

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Smolen, J. S., Kremer, J. M., Gaich, C. L., DeLozier, A. M., Schlichting, D. E., Xie, L., … Combe, B. (2017). Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). ANNALS OF THE RHEUMATIC DISEASES, 76(4).

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
Kivitz, A. J., Gutierrez-Urena, S. R., Poiley, J., Genovese, M. C., Kristy, R., Shay, K., … Zubrzycka-Sienkiewicz, A. (2017). Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY, 69(4), 709–19.

Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot trial.
Chung, L., Genovese, M. C., & Fiorentino, D. (2005). Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot trial. ARTHRITIS AND RHEUMATISM, 52(12), 4088.

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Cohen, S., Genovese, M. C., Choy, E., Perez-Ruiz, F., Matsumoto, A., Pavelka, K., … Kaur, P. (2017). Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. ANNALS OF THE RHEUMATIC DISEASES, 76(10), 1679–87.

Efficacy and Safety Analysis by Overall Anti-drug Antibody Result up to Week 30 in Patients with Rheumatoid Arthritis Treated with SB2 (an Infliximab Biosimilar) or Reference Infliximab in a Phase III Study
Choe, J.-Y., Smolen, J., Keystone, E., Genovese, M., Lee, Y., Rho, Y.-H., & Therrien, F. (2017). Efficacy and Safety Analysis by Overall Anti-drug Antibody Result up to Week 30 in Patients with Rheumatoid Arthritis Treated with SB2 (an Infliximab Biosimilar) or Reference Infliximab in a Phase III Study. JOURNAL OF RHEUMATOLOGY, 44(6), 872.

Molecular Features Define Unique Sjogren's Syndrome Patient Subsets
James, J. A., Guthridge, J. M., Chen, H., Lu, R., Bourn, R. L., Baer, A. N., … Sivils, K. L. (2017). Molecular Features Define Unique Sjogren's Syndrome Patient Subsets. ARTHRITIS & RHEUMATOLOGY, 69.

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Genovese, M. C., Pacheco-Tena, C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., … Alten, R. (2018). Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. The Journal of Rheumatology.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Genovese, M. C., van Adelsberg, J., Fan, C., Graham, N. M., van Hoogstraten, H., Parrino, J., … van der Heijde, D. (2018). Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology (Oxford, England).

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
Genovese, M. C., Kremer, J. M., Kartman, C. E., Schlichting, D. E., Xie, L., Carmack, T., … Smolen, J. S. (2018). Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford, England), 57(5), 900–908.

Adalimumab inhibited radiographic progression more effectively than methotrexate in early RA patients who had achieved a normal c-reactive protein concentration
Emery, P., Genovese, M., van Vollenhoven, R., Ozol-Godfrey, A., & Sasso, E. H. (2008). Adalimumab inhibited radiographic progression more effectively than methotrexate in early RA patients who had achieved a normal c-reactive protein concentration. ARTHRITIS AND RHEUMATISM, 58(9), S536.

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
Kremer, J. M., Schiff, M., Muram, D., Zhong, J., Alam, J., & Genovese, M. C. (2018). Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD OPEN, 4(1).

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Genovese, M. C., Combe, B., Kremer, J., Adams, D., Lee, C., Kerr, L., & Nash, P. (2017). Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study. ARTHRITIS & RHEUMATOLOGY, 69.

Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
Genovese, M. C., Kremer, J., Zhong, S., & Friedman, A. (2017). Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study. ARTHRITIS & RHEUMATOLOGY, 69.

Transaminase Levels and Hepatic Events During Tocilizumab Treatment Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis
Genovese, M. C., Kremer, J. M., van Vollenhoven, R. F., Alten, R., Jose Scali, J., Kelman, A., … Brockwell, L. (2017). Transaminase Levels and Hepatic Events During Tocilizumab Treatment Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 69(9), 1751–61.

SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
Burmester, G. R., Garg, A., Van Hoogstraten, H., Graham, N., Boddy, A., Parrino, J., & Genovese, M. C. (2016). SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS. INTERNAL MEDICINE JOURNAL, 46, 40–41.

Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
Genovese, M. C., Mease, P., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A., Deodhar, A. A., … Nirula, A. (2014). Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody. ARTHRITIS & RHEUMATOLOGY, 66, S687.

Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs.
Dawes, P., Dimic, A., Genovese, M. C., van der Heijde, D., Jenkins, M., O'Brien, C., … Weinblatt, M. (2013). Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs. ARTHRITIS AND RHEUMATISM, 65, S198–S199.

Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials.
Han, C., Keystone, E., Fleischmann, R., Smolen, J. S., Emery, P., Genovese, M. C., … Hsia, E. C. (2012). Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials. ARTHRITIS AND RHEUMATISM, 64(10), S35–S36.

Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al Reply
Emery, P., Conaghan, P. G., Fleischmann, R., van der Heijde, D., Keystone, E. C., Genovese, M. C., … Rahman, M. U. (2012). Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al Reply. ARTHRITIS AND RHEUMATISM, 64(4), 1298–99.

Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: Analysis of five phase 3 clinical trials
Genovese, M. C., Smolen, J. S., Emery, P., Jones, G., Lee, J. S., Alecock, E., & Kremer, J. M. (2008). Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: Analysis of five phase 3 clinical trials. ARTHRITIS AND RHEUMATISM, 58(9), S531–S532.

Efficacy after Transition to SB5 from Reference Adalimumab (Humira (R)) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study
Genovese, M. C., Weinblatt, M., Keystone, E. C., Baranauskaite, A., Cheong, S. Y., & Ghil, J. (2016). Efficacy after Transition to SB5 from Reference Adalimumab (Humira (R)) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study. ARTHRITIS & RHEUMATOLOGY, 68.

Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies
Kremer, J., Dougados, M., Genovese, M. C., Emery, P., Yang, L., de Bono, S., … Smolen, J. S. (2015). Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies. ARTHRITIS & RHEUMATOLOGY, 67.

Immunogenicity Is Low and Transient with Intravenous (IV) Abatacept Therapy: Results From a Large Pooled Analysis of 3985 Patients (pts) with Rheumatoid Arthritis (RA) and up to 8 Years' Exposure
Weinblatt, M. E., Genovese, M. C., Schiff, M. H., Westhovens, R., Alten, R., Delaet, I., … Kremer, J. M. (2011). Immunogenicity Is Low and Transient with Intravenous (IV) Abatacept Therapy: Results From a Large Pooled Analysis of 3985 Patients (pts) with Rheumatoid Arthritis (RA) and up to 8 Years' Exposure. ARTHRITIS AND RHEUMATISM, 63(10), S854.

LONG-TERM EXTENSION STUDIES OF TOCILIZUMAB IN RA: SAFETY AND TOLERABILITY
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Scali, J., Zilberstein, M., Vernon, E., & Vollenhoven, R. (2011). LONG-TERM EXTENSION STUDIES OF TOCILIZUMAB IN RA: SAFETY AND TOLERABILITY. RHEUMATOLOGY, 50, 33.

Edward D. Harris, Jr., MD, 1937-2010 IN MEMORIAM
Genovese, M. C., & Moynihan, E. M. (2010). Edward D. Harris, Jr., MD, 1937-2010 IN MEMORIAM. ARTHRITIS AND RHEUMATISM, 62(9), 2623–24.

EFFICACY OF GOLIMUMAB, A HUMAN ANTI-TNF alpha ANTIBODY, BY BASELINE CRP LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
Emery, P., Genovese, M. C., Fleischmann, R. M., Matteson, E. L., Hsia, E. C., Xu, S., … Rahman, M. U. (2010). EFFICACY OF GOLIMUMAB, A HUMAN ANTI-TNF alpha ANTIBODY, BY BASELINE CRP LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. RHEUMATOLOGY, 49, I101.

Secukinumab in Active Rheumatoid Arthritis after Anti-TNF alpha Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
Tahir, H., Deodhar, A., Genovese, M., Takeuchi, T., Aelion, J., Van den Bosch, F., … Richards, H. B. (2017). Secukinumab in Active Rheumatoid Arthritis after Anti-TNF alpha Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. RHEUMATOLOGY AND THERAPY, 4(2), 475–88.

Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Keystone, E., Taylor, P., Genovese, M., Schlichting, D., de la Torre, I., Beattie, S., & Rooney, T. (2015). Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 42(7), 1292.

VALIDATION OF REMISSION OF RHEUMATOID ARTHRITIS BY TRADITIONAL DISEASE ACTIVITY SCORE AND PROVISIONAL CRITERIA BY AMERICAN COLLEGE OF RHEUMATOLOGY AND EUROPEAN LEAGUE AGAINST RHEUMATISM: ANALYSIS BASED ON PATIENT-REPORTED OUTCOMES ANALYSED FROM THREE PHASE III GOLIMUMAB CLINICAL TRIALS
Han, C., Keystone, E. C., Fleischmann, R., Smolen, J., Emery, P., Genovese, M., … Hsia, E. C. (2013). VALIDATION OF REMISSION OF RHEUMATOID ARTHRITIS BY TRADITIONAL DISEASE ACTIVITY SCORE AND PROVISIONAL CRITERIA BY AMERICAN COLLEGE OF RHEUMATOLOGY AND EUROPEAN LEAGUE AGAINST RHEUMATISM: ANALYSIS BASED ON PATIENT-REPORTED OUTCOMES ANALYSED FROM THREE PHASE III GOLIMUMAB CLINICAL TRIALS. RHEUMATOLOGY, 52, 83.

One Year Efficacy and Safety Results of a Phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis.
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., … Mpofu, S. (2011). One Year Efficacy and Safety Results of a Phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 63(10), S149–S150.

GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN RA (GO-FORWARD STUDY)
Rubbert, A., Genovese, M. C., Keystone, E., Hsia, E. C., Buchanan, J., Klareskog, L., … Rahman, M. U. (2009). GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN RA (GO-FORWARD STUDY). RHEUMATOLOGY, 48, I84.

Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients
Genovese, M. C., Galien, R., Pan, Y., Van der Aa, A., Jamoul, C., Harrison, P., … Tarrant, J. (2017). Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients. ARTHRITIS & RHEUMATOLOGY, 69.

Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies
Genovese, M. C., Van der Aa, A., Jamoul, C., Tasset, C., Harrison, P., Westhovens, R., & Kavanaugh, A. (2017). Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies. ARTHRITIS & RHEUMATOLOGY, 69.

Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis.
Genovese, M. C., Kremer, J. M., van Vollenhoven, R. F., Alten, R., Jose Scali, J., Kelman, A., … Pitts, L. (2013). Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 65, S201.

Safety of tnf inhibitors and non-biologic DMARDs in rheumatoid arthritis patients previously treated with rituximab
Emery, P., Genovese, M. C., Breedveld, F., Moreland, L., Keystone, E., Matteson, E. L., … Shaw, T. (2008). Safety of tnf inhibitors and non-biologic DMARDs in rheumatoid arthritis patients previously treated with rituximab. RHEUMATOLOGY, 47, II48–II49.

Safety of Other Biologic Therapies Following Rituximab Treatment in RA Patients
Khraishi, M., Genovese, M. C., & Breedveld, F. (2009). Safety of Other Biologic Therapies Following Rituximab Treatment in RA Patients. JOURNAL OF RHEUMATOLOGY, 36(11), 2598–99.

Efficacy and safety of up to 10 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis
Weinblatt, M., Genovese, M., Moreland, L., & Bathon, J. (2008). Efficacy and safety of up to 10 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 58(2), AB47.

Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
Genovese, M. C., Fay, J., Parrino, J., Beyer, D., Iglesias-Rodriguez, M., Graham, N., … Burmester, G. R. (2016). Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients. ARTHRITIS & RHEUMATOLOGY, 68.

Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older
Fleischmann, R., Genovese, M. C., van Adelsberg, J., Mangan, E., Iglesias-Rodriguez, M., Dukovic, D., & Huizinga, T. W. J. (2016). Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older. ARTHRITIS & RHEUMATOLOGY, 68.

Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Weinblatt, M. E., Bathon, J. M., Hooper, M., Bitman, B., Yang, Y., Collier, D. H., … Genovese, M. C. (2013). Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept. ARTHRITIS AND RHEUMATISM, 65, S986–S987.

EVALUATION OF JOINT DAMAGE IN RA PATIENTS TREATED WITH RITUXIMAB: COMPARISON OF GENANT- AND VAN DER HEIJDE-MODIFIED SHARP RADIOGRAPHIC SCORING
Genovese, M., Peterfy, C., Emery, P., Keystone, E., Tak, P.-P., Cohen, S. B., … Shaw, T. (2009). EVALUATION OF JOINT DAMAGE IN RA PATIENTS TREATED WITH RITUXIMAB: COMPARISON OF GENANT- AND VAN DER HEIJDE-MODIFIED SHARP RADIOGRAPHIC SCORING. RHEUMATOLOGY, 48, I65.

Safety and Efficacy of ABT-122, a TNF and IL-17-Targeted Dual Variable Domain (DVD)-Ig (TM), in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Mease, P. J., Genovese, M. C., Weinblatt, M., Peloso, P. M., Chen, K., Li, Y., … Padley, R. J. (2016). Safety and Efficacy of ABT-122, a TNF and IL-17-Targeted Dual Variable Domain (DVD)-Ig (TM), in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial. ARTHRITIS & RHEUMATOLOGY, 68.

Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis.
Keystone, E. C., Taylor, P. C., Genovese, M. C., Schlichting, D. E., De La Torre, I., Beattie, S. D., & Rooney, T. (2014). Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 66, S1232.

Reversibility of pharmacodynamic effects after short and long-term treatment with tofacitinib in patients with rheumatoid arthritis.
Genovese, M. C., Kawabata, T. T., Soma, K., Menon, S., Clark, J. D., Hodge, J. A., … Krishnaswami, S. (2014). Reversibility of pharmacodynamic effects after short and long-term treatment with tofacitinib in patients with rheumatoid arthritis. PHARMACOTHERAPY, 34(10), E225–E226.

Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis
Komocsar, W. J., Genovese, M. C., Dow, E. R., Banerjee, P., Penny, M. A., Nantz, E. P., … Hoffman, R. W. (2012). Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S565.

IMPACT OF GOLIMUMAB ON PHYSICAL FUNCTION, HEALTH-RELATED QOL, PRODUCTIVITY AND EMPLOYMENT IN RA PATIENTS: WEEK 52 RESULTS FROM GO-FORWARD
Genovese, M. C., Rubbert, A., Keystone, E. C., Hsia, E. C., Buchanan, J., Klareskog, L., … Rahman, M. U. (2010). IMPACT OF GOLIMUMAB ON PHYSICAL FUNCTION, HEALTH-RELATED QOL, PRODUCTIVITY AND EMPLOYMENT IN RA PATIENTS: WEEK 52 RESULTS FROM GO-FORWARD. RHEUMATOLOGY, 49, I109–I110.

EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSIONOF A PHASE III MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Burrnester, G. R., Fiore, S., Hu, C.-C., Fay, J., Lee, E. B., & Genovese, M. C. (2018). EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSIONOF A PHASE III MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. RHEUMATOLOGY, 57.

Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis
Genovese, M. C., Mangan, E. K., Kimura, T., Iglesias-Rodriguez, M., & Huizinga, T. W. J. (2017). Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 69.

Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients
Genovese, M. (2015). Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients. JOURNAL OF RHEUMATOLOGY, 42(10), 1994.

Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist.
Genovese, M., van der Heijde, D., Keystone, E., Spindler, A., Benhamou, C.-L., Kavanaugh, A., … Weinblatt, M. (2013). Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist. ARTHRITIS AND RHEUMATISM, 65, S199–S200.

Phenotypic and functional features of th-17 cells in psoriasis and psoriatic arthritis
Raychaudhuri, S. P., Raychaudhuti, S. K., & Genovese, M. C. (2008). Phenotypic and functional features of th-17 cells in psoriasis and psoriatic arthritis. ARTHRITIS AND RHEUMATISM, 58(9), S352.

Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira (R); RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
Genovese, M. C., Glover, J., Matsunaga, N., Chisholm, D., & Alten, R. (2017). Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira (R); RP) in Patients (pts) with Active Rheumatoid Arthritis (RA). ARTHRITIS & RHEUMATOLOGY, 69.

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Chalabi, Y., Peterfy, C., Genovese, M., Emery, P., Taylor, P., Schlichting, D., … Keystone, E. (2014). Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 41(7), 1506.

Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients.
Ptacek, J., Hawtin, R., Louie, B., Evensen, E., Cordeiro, J., Mittleman, B., … Bridges, S. L. (2013). Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients. ARTHRITIS AND RHEUMATISM, 65, S974–S975.

LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS CLINICAL TRIALS
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Scali, J., Zilberstein, M., Thompson, L., & Van Vollenhoven, R. (2012). LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS CLINICAL TRIALS. RHEUMATOLOGY, 51, 75–76.

SECUKINUMAB TREATMENT PROVIDES SUSTAINED RESPONSE OVER ONE YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS
Durez, P., Genovese, M. C., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., … Mpofu, S. (2012). SECUKINUMAB TREATMENT PROVIDES SUSTAINED RESPONSE OVER ONE YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS. RHEUMATOLOGY, 51, 29.

Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study
Genovese, M. C., Kivitz, A. J., Simon Campos, J. A., Rell-Bakalarska, M., Fleischmann, R. M., Jasson, M., … Huizinga, T. W. J. (2011). Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study. ARTHRITIS AND RHEUMATISM, 63(12), 4041–42.

GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Wordsworth, P., Buchanan, J., Fleischmann, R., Genovese, M., Kay, J., Hsia, E., … Parasuraman, S. (2009). GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. RHEUMATOLOGY, 48, I83.

Tocilizmab treatment results in rapid improvements in the signs and symptoms of moderate-to-severe rheumatoid arthritis in four patient Populations with different prior therapy exposure
Smolen, J. S., Churchill, M., Rizzo, W., Ridley, D., Law, A., Bahrt, K., & Genovese, M. C. (2008). Tocilizmab treatment results in rapid improvements in the signs and symptoms of moderate-to-severe rheumatoid arthritis in four patient Populations with different prior therapy exposure. ARTHRITIS AND RHEUMATISM, 58(9), S532–S533.

Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study
Genovese, M. C., Stanislav, M., van Hoogstraten, H., Martincova, R., Fan, C., & van Adelsberg, J. (2015). Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study. ARTHRITIS & RHEUMATOLOGY, 67.

FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE
Keystone, E., Genovese, M. C., Hall, S., Miranda, P. C., Bae, S.-C., Han, C., … Hsia, E. C. (2014). FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE. RHEUMATOLOGY, 53, 99.

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate.
Genovese, M. C., Greenwald, M., Codding, C., Cardiel, M. H., Zubrzycka-Sienkiewicz, A., Kivitz, A. J., … Garg, J. P. (2014). A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate. ARTHRITIS & RHEUMATOLOGY, 66, S1234–S1235.

Long-Term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials.
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Scali, J., Zilberstein, M., Thompson, L., & van Vollenhoven, R. F. (2011). Long-Term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials. ARTHRITIS AND RHEUMATISM, 63(10), S866.

Effects of the Oral SYK Inhibitor, Fostamatinib (R788), on Health-Related Quality of Life in a Phase II Study of Active Rheumatoid Arthritis.
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2011). Effects of the Oral SYK Inhibitor, Fostamatinib (R788), on Health-Related Quality of Life in a Phase II Study of Active Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 63(10), S158–S159.

DURABILITY, MAINTENANCE AND EFFECTS OF DOSE REDUCTION FOLLOWING PROLONGED TREATMENT WITH BARICITINIB
Smolen, J. S., Dougados, M., Takeuchi, T., Genovese, M. C., Haraoui, B., Klar, R., … van Vollenhoven, R. (2018). DURABILITY, MAINTENANCE AND EFFECTS OF DOSE REDUCTION FOLLOWING PROLONGED TREATMENT WITH BARICITINIB. RHEUMATOLOGY, 57.

ABT-122, a Tnf- and IL-17-Targeted Dual Variable Domain (DVD)-Ig (TM) in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Genovese, M. C., Weinblatt, M., Aelion, J. A., Mansikka, H. T., Peloso, P. M., Chen, K., … Padley, R. J. (2016). ABT-122, a Tnf- and IL-17-Targeted Dual Variable Domain (DVD)-Ig (TM) in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial. ARTHRITIS & RHEUMATOLOGY, 68.

Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study
Genovese, M., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., … Bookman, A. (2016). Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study. JOURNAL OF RHEUMATOLOGY, 43(6), 1188.

EFFICACY AND SAFETY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICS AND IN THOSE WHO ARE BIOLOGIC-NAIVE
Fleischmann, R., Genovese, M., Fan, C., Fiore, S., & Decktor, D. (2016). EFFICACY AND SAFETY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICS AND IN THOSE WHO ARE BIOLOGIC-NAIVE. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 22(3), 122.

SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S. B., Keystone, E., Matteson, E. L., … Shaw, T. (2011). SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB. RHEUMATOLOGY, 50, 126.

Repeat treatment with rituximab in active RA patients: Long-term efficacy in patients with one versus two or more prior TNF inhibitors
Emery, P., Kremer, J. M., Tony, H. P., Genovese, M. C., Tak, P.-P., Luggen, M., … Safa-Leathers, S. (2008). Repeat treatment with rituximab in active RA patients: Long-term efficacy in patients with one versus two or more prior TNF inhibitors. RHEUMATOLOGY, 47, II38.

Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis
Kremer, J. M., Genovese, M. C., Muram, D., Zhong, J., Alam, J., & Schiff, M. (2016). Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 68.

Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials
Han, C., Keystone, E. C., Fleischmann, R., Smolen, J. S., Matteson, E. L., Emery, P., … Hsia, E. C. (2014). Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials. ARTHRITIS & RHEUMATOLOGY, 66, S1090.

SUBCUTANEOUS ABATACEPT VERSUS INTRAVENOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: LONG-TERM DATA FROM THE ACQUIRE TRIAL
Genovese, M. C., Covarrubias Cobos, A., Leon, G., Mysler, E. F., Keiserman, M. W., Valente, R. M., … Alten, R. (2012). SUBCUTANEOUS ABATACEPT VERSUS INTRAVENOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: LONG-TERM DATA FROM THE ACQUIRE TRIAL. RHEUMATOLOGY, 51, 128–29.

Independent Predictors for the Development of Upper Gastrointestinal Ulcers: Results from Two 24-Week Double-Blind Trials of a Single-Tablet Combination of Ibuprofen-Famotidine vs. Ibuprofen Alone
Laine, L., Schiff, M., Genovese, M., Kivitz, A., Bello, A., Grahn, A., … Weinblatt, M. (2009). Independent Predictors for the Development of Upper Gastrointestinal Ulcers: Results from Two 24-Week Double-Blind Trials of a Single-Tablet Combination of Ibuprofen-Famotidine vs. Ibuprofen Alone. AMERICAN JOURNAL OF GASTROENTEROLOGY, 104, S535–S536.

IMPROVEMENTSIN REMISSION AND LOW DISEASE ACTIVITY ARE ACHIEVED WITH ONGOING SARILUMABTREATMENT, IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TWO PHASE III STUDIES
Genovese, M. C., Mangan, E. K., Fay, J., Kimura, T., van Hoogstraten, H., & Fleischmann, R. (2018). IMPROVEMENTSIN REMISSION AND LOW DISEASE ACTIVITY ARE ACHIEVED WITH ONGOING SARILUMABTREATMENT, IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TWO PHASE III STUDIES. RHEUMATOLOGY, 57.

Efficacy of Sarilumab Plus csDMARDs in Rheumatoid Arthritis Patients who had an Inadequate Response to One or More than One Prior TNF Inhibitor
Genovese, M., Pinheiro, G., Mangan, E., Lin, Y., van Adelsberg, J., van Hoogstraten, H., … Fiore, S. (2017). Efficacy of Sarilumab Plus csDMARDs in Rheumatoid Arthritis Patients who had an Inadequate Response to One or More than One Prior TNF Inhibitor. JOURNAL OF RHEUMATOLOGY, 44(6), 896.

Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards
Genovese, M. C., Ogata, A., Nomura, A., Bao, M., Hitraya, E., Lacey, S., & Burmester, G. (2015). Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards. ARTHRITIS & RHEUMATOLOGY, 67.

SAFETY OF OTHER BIOLOGIC THERAPIES FOLLOWING RITUXIMAB TREATMENT IN RA PATIENTS
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S. B., Keystone, E., Matteson, E., … Shaw, T. (2009). SAFETY OF OTHER BIOLOGIC THERAPIES FOLLOWING RITUXIMAB TREATMENT IN RA PATIENTS. RHEUMATOLOGY, 48, I90–I91.

GOLIMUMAB ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS IN ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE: WEEK 24 RESULTS OF GO-FORWARD STUDY
Rubbert, A., Keystone, E., Genovese, M., Klareskog, L., Hsia, E. C., Zrubek, J., … Rahman, M. U. (2009). GOLIMUMAB ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS IN ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE: WEEK 24 RESULTS OF GO-FORWARD STUDY. RHEUMATOLOGY, 48, I92.

CONTINUED INHIBITION OF STRUCTURAL DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB AT 2 YEARS: REFLEX STUDY
Cohen, S. B., Keystone, E. C., Genovese, M., Emery, P., Peterfy, C., Tak, P.-P., … Hagerty, D. (2009). CONTINUED INHIBITION OF STRUCTURAL DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB AT 2 YEARS: REFLEX STUDY. RHEUMATOLOGY, 48, I88.

Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Genovese, M. C., Durez, P., Fleischmann, R., Tanaka, Y., Furst, D. E., Yamanaka, H., … Takeuchi, T. (2016). Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes. ARTHRITIS & RHEUMATOLOGY, 68.

EFFICACY AND SAFETY OF SARILUMAB IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS FROM 2 PHASE 3 STUDIES
Genovese, M. C., Fleischmann, R., Mangan, E. K., van Adelsberg, J., Iglesias-Rodriguez, M., Fan, C., & Huizinga, T. W. (2017). EFFICACY AND SAFETY OF SARILUMAB IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS FROM 2 PHASE 3 STUDIES. RHEUMATOLOGY, 56, 137–38.

Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Genovese, M. C., Fleischmann, R. M., Jasson, M., Radin, A. R., Hamilton, J., & Huizinga, T. W. J. (2012). Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S568.

Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies
Genovese, M. C., Mangan, E. K., Fay, J., Kimura, T., van Hoogstraten, H., & Fleischmann, R. (2017). Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies. ARTHRITIS & RHEUMATOLOGY, 69.

Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)
Strand, V., Rendas-Baum, R., Joseph, G. J., Chen, C.-I., van Hoogstraten, H., Huizinga, T. W. J., & Genovese, M. C. (2015). Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT). ARTHRITIS & RHEUMATOLOGY, 67.

Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
Baker, M., Chalabi, Y., Genovese, M., Taylor, P., Schlichting, D., Beattie, S., … Keystone, E. (2014). Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study. JOURNAL OF RHEUMATOLOGY, 41(7), 1505.

Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis
Genovese, M. C., Mease, P. J., Viswanathan, H., Chau, D., Feng, J. Y., Erondu, N., & Nirula, A. (2013). Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis. ARTHRITIS AND RHEUMATISM, 65, S136.

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
Keystone, E. C., Genovese, M. C., Schlichting, D. E., de la Torre, I., Beattie, S. D., Rooney, T. P., & Taylor, P. C. (2018). Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 45(1), 14–21.

CLINICAL AND RADIOGRAPHIC OUTCOMES AFTER 3 YEARS OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
Genovese, M. C., van Adelsberg, J., van Hoogstraten, H., Iglesias-Rodriguez, M., Mangan, E. K., Graham, N., & Spindler, A. (2017). CLINICAL AND RADIOGRAPHIC OUTCOMES AFTER 3 YEARS OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS. RHEUMATOLOGY, 56, 27–28.

A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.
Kavanaugh, A., Decktor, D. L., Fan, C., van Adelsberg, J., Martincova, R., & Genovese, M. C. (2014). A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study. ARTHRITIS & RHEUMATOLOGY, 66, S1233–S1234.

Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years.
Genovese, M. C., Sebba, A., Rubbert-Roth, A., Jose Scali, J., Alten, R., Kremer, J. M., … van Vollenhoven, R. F. (2012). Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years. ARTHRITIS AND RHEUMATISM, 64(10), S700–S701.

Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: Analysis of five phase 3 clinical trials
Genovese, M. C., Smolen, J. S., Emery, P., Jones, G., Lee, J. S., Alecock, E., & Kremer, J. M. (2008). Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: Analysis of five phase 3 clinical trials. ARTHRITIS AND RHEUMATISM, 58(9), S785–S786.

The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies
Genovese, M. C., Westhovens, R., Kavanaugh, A., Meuleners, L., Van der Aa, A., Harrison, P., & Tasset, C. (2016). The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies. ARTHRITIS & RHEUMATOLOGY, 68.

Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis.
Keystone, E., Genovese, M. C., Taylor, P., Zhu, B., Beattie, S. D., de Bono, S., … Macias, W. (2013). Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 65, S607.

Longterm Remission with Golimumab in Active Rheumatoid Arthritis Patients Despite Methotrexate Through 2 Years
Keystone, E., Genovese, M., Klareskog, L., Xu, S., Han, C., & Hsia, E. (2013). Longterm Remission with Golimumab in Active Rheumatoid Arthritis Patients Despite Methotrexate Through 2 Years. JOURNAL OF RHEUMATOLOGY, 40(6), 968.

Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Cohen, S. B., Genovese, M. C., Choy, E. H., Perez-Ruiz, F., Pablos, J. L., Zhang, N., & Kaur, P. (2015). Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 67.

Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Kremer, J., Genovese, M., Keystone, E., Taylor, P., Zuckerman, S., Schlichting, D., … Macias, W. (2015). Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 42(7), 1291.

Improved remission rates with the IL-6R inhibitor tocilizumab (TCZ) in patients with active rheumatoid arthritis despite DMARD therapy: The toward study
Genovese, M. C., Mckay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., … Gomez-Reino, J. J. (2008). Improved remission rates with the IL-6R inhibitor tocilizumab (TCZ) in patients with active rheumatoid arthritis despite DMARD therapy: The toward study. RHEUMATOLOGY, 47, II50.

SAFETY SUMMARY RESULTS OF BARICITINIB FOCUSING ON SERIOUS INFECTIONS EVENTS AND PRESELECTED COMORBIDITIES
Combe, B., Balsa, A., Winthrop, K., Tony, H.-P., Genovese, M. C., Harigai, M., … Dougados, M. (2018). SAFETY SUMMARY RESULTS OF BARICITINIB FOCUSING ON SERIOUS INFECTIONS EVENTS AND PRESELECTED COMORBIDITIES. RHEUMATOLOGY, 57.

Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis.
Mease, P., Genovese, M. C., Mutebi, A., Wilson, H., Revicki, D., Erondu, N., … Viswanathan, H. (2014). Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis. ARTHRITIS & RHEUMATOLOGY, 66, S240.

12-and 24-Week Patient-Reported Outcomes from a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Chalabi, Y., Smolen, J., Taylor, P., Genovese, M., Lee, C., Schlichting, D., … Keystone, E. (2014). 12-and 24-Week Patient-Reported Outcomes from a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 41(7), 1498–99.

Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling
Ptacek, J., Hawtin, R., Louie, B., Evensen, E., Cordeiro, J., Mittleman, B., … Bridges, S. L. (2013). Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling. ARTHRITIS AND RHEUMATISM, 65, S375.

Efficacy and safety of up to 10 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis
Weinblatt, M., Bathon, J., Kremer, J., & Genovese, M. (2009). Efficacy and safety of up to 10 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 60(3), AB56.

Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Fiore, S., Genovese, M., Fan, C., Decktor, D., & Fleischmann, R. (2016). Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-blind, Placebo-Controlled Study. JOURNAL OF RHEUMATOLOGY, 43(6), 1217.

IMMUNOGENICITY OF SUBCUTANEOUS AND INTRAVENOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
Genovese, M. C., Ogata, A., Nomura, A., Bao, M., Hitraya, E., Lacey, S., & Burmester, G. R. (2016). IMMUNOGENICITY OF SUBCUTANEOUS AND INTRAVENOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS. RHEUMATOLOGY, 55, 92–93.

Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
Genovese, M. C., Mease, P. J., Greenwald, M., Ritchlin, C. T., Beaulieu, A., Deodhar, A. A., … Nirula, A. (2015). Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis. ARTHRITIS & RHEUMATOLOGY, 67.

Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Keystone, E., Genovese, M. C., Hall, S., Miranda, P., Bae, S.-C., Han, C., … Hsia, E. C. (2013). Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate. ARTHRITIS AND RHEUMATISM, 65, S597–S598.

The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes
Genovese, M. C., Fleischmann, R., Hagino, O., Hu, C.-C., Pena-Rossi, C., Sadeh, J., … Mandrup-Poulsen, T. (2017). The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes. ARTHRITIS & RHEUMATOLOGY, 69.

SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS
Genovese, M. C., Fay, J., Parrino, J., Beyer, D., Iglesias-Rodriguez, M., Graham, N., … Burmester, G. R. (2017). SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS. RHEUMATOLOGY, 56, 139.

Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Genovese, M., Weinblatt, M., Keystone, E., Baranauskaite, A., Cheong, S.-Y., & Ghil, J. (2017). Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy. JOURNAL OF RHEUMATOLOGY, 44(6), 878.

Telomere Damage in Rheumatoid Arthritis
Li, Y., Ju, J., Bush, T. M., Genovese, M. C., Goronzy, J., & Weyand, C. M. (2015). Telomere Damage in Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 67.

BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
Taylor, P., Genovese, M., Keystone, E., Schlichting, D., Beattie, S., & Macias, W. (2014). BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY. ANNALS OF THE RHEUMATIC DISEASES, 73, A31.

Longer-Term Safety of Fostamatinib (R788) in Patients with Rheumatoid Arthritis-Analysis of Clinical Trial Data From up to 2 Years of Exposure.
Kavanaugh, A., Weinblatt, M. E., Genovese, M. C., Musser, T. K., Grossbard, E. B., Magilavy, D. B., … Millson, D. (2011). Longer-Term Safety of Fostamatinib (R788) in Patients with Rheumatoid Arthritis-Analysis of Clinical Trial Data From up to 2 Years of Exposure. ARTHRITIS AND RHEUMATISM, 63(10), S1018–S1019.

Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Burmester, G. R., Fiore, S., Hu, C.-C., Fay, J., Lee, E. B., & Genovese, M. C. (2017). Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 69.

Clinical and Radiographic Outcomes After 3 Years of Sarilumab in Patients with Rheumatoid Arthritis
Genovese, M., van Adelsberg, J., van Hoogstraten, H., Iglesias-Rodriguez, M., Mangan, E., Graham, N., … Fiore, S. (2017). Clinical and Radiographic Outcomes After 3 Years of Sarilumab in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 44(6), 895.

Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Kremer, J. M., Genovese, M. C., Keystone, E. C., Taylor, P. C., Zuckerman, S. H., Schlichting, D. E., … Macias, W. L. (2014). Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 66, S210.

Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis following a Mean Treatment Duration of 3.9 Years
Haraoui, B., Sebba, A., Rubbert-Roth, A., Scali, J., Alten, R., Kremer, J., … Genovese, M. (2014). Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis following a Mean Treatment Duration of 3.9 Years. JOURNAL OF RHEUMATOLOGY, 41(7), 1508.

Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
Genovese, M. C., Silverman, G. J., Emery, P., Gupta, R., Gill, A., Komocsar, W. J., … Lee, C. (2013). Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study. ARTHRITIS AND RHEUMATISM, 65, S733–S734.

Tocilizumab Monotherapy and Tocilizumab Plus Disease-Modifying Antirheumatic Drugs in a US Rheumatoid Arthritis Population with Inadequate Response to Anti-Tumor Necrosis Factor Agents.
Weinblatt, M. E., Kremer, J. M., Cush, J. J., Rigby, W., Teng, L., Singh, N., … Genovese, M. C. (2011). Tocilizumab Monotherapy and Tocilizumab Plus Disease-Modifying Antirheumatic Drugs in a US Rheumatoid Arthritis Population with Inadequate Response to Anti-Tumor Necrosis Factor Agents. ARTHRITIS AND RHEUMATISM, 63(10), S162.

Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Genovese, M. C., Kavanaugh, A., Winthrop, K., Greenwald, M., Ponce, L., Enriquez Sosa, F., … Alten, R. (2017). Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study. ARTHRITIS & RHEUMATOLOGY, 69.

Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Genovese, M. C., Kremer, J. M., Kartman, C., Schlichting, D. E., Xie, L., Carmack, T., … Smolen, J. S. (2015). Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors. ARTHRITIS & RHEUMATOLOGY, 67.

Low immunogenic potential of tocilizumab in patients with rheumatoid arthritis: Analysis of four phase 3 clinical trials
Ramos-Remus, C., Genovese, M. C., Harre, R. A., Woodworth, T., & Alecock, E. (2008). Low immunogenic potential of tocilizumab in patients with rheumatoid arthritis: Analysis of four phase 3 clinical trials. ARTHRITIS AND RHEUMATISM, 58(9), S534.

Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies
Genovese, M. C., Fleischmann, R., Mangan, E., van Adelsberg, J., Iglesias-Rodriguez, M., Dukovic, D., … Huizinga, T. W. J. (2016). Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies. ARTHRITIS & RHEUMATOLOGY, 68.

Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
Genovese, M. C., Mease, P. J., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A., Deodhar, A., … Nirula, A. (2013). Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis. ARTHRITIS AND RHEUMATISM, 65, S347–S348.

American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al Reply
Genovese, M. C. (2011). American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al Reply. ARTHRITIS AND RHEUMATISM, 63(10), 3182.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., … Genovese, M. (2017). Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. LANCET, 389(10086), 2317–27.

Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients
Burmester, G., Garg, A., van Hoogstraten, H., Graham, N., Boddy, A., Parrino, J., & Genovese, M. C. (2015). Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients. ARTHRITIS & RHEUMATOLOGY, 67.

Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.
Fleischmann, R., Decktor, D. L., Fan, C., Van Hoogstraten, H., & Genovese, M. C. (2014). Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study. ARTHRITIS & RHEUMATOLOGY, 66, S1232–S1233.

Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
Genovese, M. C., Carlier, H., Erickson, J., Braun, D., & Banerjee, S. (2013). Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study. ARTHRITIS AND RHEUMATISM, 65, S188.

Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From 3 Phase III Studies
Han, C., Kavanaugh, A., Genovese, M. C., Hsu, B., Deodhar, A. A., & Hsia, E. C. (2013). Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From 3 Phase III Studies. ARTHRITIS AND RHEUMATISM, 65, S137.

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis
Genovese, M. C., Smolen, J. S., Takeuchi, T., Hyslop, D., Macias, W. L., Rooney, T. P., … Winthrop, K. (2017). Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis. ARTHRITIS & RHEUMATOLOGY, 69.

Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients
Genovese, M., Fay, J., Parrino, J., Beyer, D., Iglesias-Rodriguez, M., van Hoogstraten, H., … Fiore, S. (2017). Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients. JOURNAL OF RHEUMATOLOGY, 44(6), 895–96.

Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Analysis Based on Patient Reported Outcomes Analyzed from 3 Phase III Golimumab Clinical Trials of Golimumab
Keystone, E., Han, C., Fleischmann, R., Smolen, J., Emery, P., Genovese, M., … Hsia, E. (2013). Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Analysis Based on Patient Reported Outcomes Analyzed from 3 Phase III Golimumab Clinical Trials of Golimumab. JOURNAL OF RHEUMATOLOGY, 40(6), 968–69.

LONG-TERM SAFETY OF TOCILIZUMAB IN RA PATIENTS TREATED FOR A MEAN DURATION OF 3.7 YEARS
Genovese, M., Sebba, A., Rubbert-Roth, A., Scali, J. J., Alten, R., Kremer, J. M., … van Vollenhoven, R. F. (2013). LONG-TERM SAFETY OF TOCILIZUMAB IN RA PATIENTS TREATED FOR A MEAN DURATION OF 3.7 YEARS. RHEUMATOLOGY, 52, 93–94.

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Genovese, M., Westhovens, R., Meuleners, L., Van der Aa, A., Harrison, P., Tasset, C., & Kavanaugh, A. (2018). Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. ARTHRITIS RESEARCH & THERAPY, 20, 57.

Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Takeuchi, T., Genovese, M. C., Haraoui, B., Li, Z., Xie, L., Klar, R., … Smolen, J. S. (2017). Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study. ARTHRITIS & RHEUMATOLOGY, 69.

Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24-Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study.
Strand, V., Joseph, G., van Hoogstraten, H., Chen, C.-I., Fan, C., Carita, P., … Genovese, M. C. (2014). Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24-Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study. ARTHRITIS & RHEUMATOLOGY, 66, S669–S670.

AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S. B., Keystone, E. C., Matteson, E. L., … Shaw, T. M. (2010). AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS. RHEUMATOLOGY, 49, I4.

RADIOGRAPHIC OUTCOMES IN PATIENTS ACHIEVING CLINICAL REMISSION OR LOW DISEASE ACTIVITY IN A PHASE 3 STUDY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE, MODERATE TO SEVERE RHEUMATOID ARTHRITIS
van Hoogstraten, H., Mangan, E. K., Fay, J., van Adelsberg, J., Fan, C., & Genovese, M. C. (2017). RADIOGRAPHIC OUTCOMES IN PATIENTS ACHIEVING CLINICAL REMISSION OR LOW DISEASE ACTIVITY IN A PHASE 3 STUDY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE, MODERATE TO SEVERE RHEUMATOID ARTHRITIS. RHEUMATOLOGY, 56, 204–5.

Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies
Emery, P., McInnes, I., Genovese, M. C., Smolen, J. S., Kremer, J., Dougados, M., … Taylor, P. C. (2015). Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies. ARTHRITIS & RHEUMATOLOGY, 67.

The AMBITION Study: Superiority Of Tocilizumab vs Methotrexate Monotherapy in Patients with Rheumatoid Arthritis
Khraishi, M., Jones, G., & Genovese, M. (2009). The AMBITION Study: Superiority Of Tocilizumab vs Methotrexate Monotherapy in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 36(11), 2574–75.

Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis
van der Heijde, D., van Adelsberg, J., van Hoogstraten, H., Iglesias-Rodriguez, M., Mangan, E., Graham, N., … Genovese, M. C. (2016). Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 68.

The Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, in Primary Sjogren's Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial
St Clair, E. W., Baer, A. N., Noaiseh, G., Parke, A., Coca, A., Utset, T., … James, J. A. (2015). The Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, in Primary Sjogren's Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial. ARTHRITIS & RHEUMATOLOGY, 67.

SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, EMPLOYABILITY AND REDUCED HEALTHCARE RESOURCE UTILIZATION OF PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS TREATED WITH GOLIMUMAB: 5-YEAR RESULTS FROM THREE PHASE III STUDIES
Han, C., Kavanaugh, A., Genovese, M. C., Deodhar, A., Hsu, B., & Hsia, E. (2014). SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, EMPLOYABILITY AND REDUCED HEALTHCARE RESOURCE UTILIZATION OF PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS TREATED WITH GOLIMUMAB: 5-YEAR RESULTS FROM THREE PHASE III STUDIES. RHEUMATOLOGY, 53, 74.

Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis
Warren, M. S., Hughes, S. G., Singleton, W., Yamashita, M., & Genovese, M. C. (2015). Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY, 17, 80.

Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin (LDA), a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials.
Weinblatt, M., Genovese, M. C., Kivitz, A., Bello, A. E., Grahn, A., Sherman, J. W., … Magelli, M. (2012). Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin (LDA), a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials. PHARMACOTHERAPY, 32(10), E203.

IL-17 receptor and its functional significance in psoriatic arthritis
Raychaudhuri, S. P., Raychaudhuri, S. K., & Genovese, M. C. (2012). IL-17 receptor and its functional significance in psoriatic arthritis. MOLECULAR AND CELLULAR BIOCHEMISTRY, 359(1-2), 419–29.

Dual Cytokine Inhibition with ABT-122, a Tnf- and IL-17-Targeted Dual Variable Domain Immunoglobulin (DVD-Ig (TM)): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis
Genovese, M. C., Weinblatt, M., Mansikka, H. T., Peloso, P. M., Chen, K., Li, Y., … Padley, R. J. (2016). Dual Cytokine Inhibition with ABT-122, a Tnf- and IL-17-Targeted Dual Variable Domain Immunoglobulin (DVD-Ig (TM)): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 68.

A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
Genovese, M. C., van Vollenhoven, R., Bloom, B. J., Jiang, J. G., & Kinnman, N. (2013). A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 65(12), 3320.

ABT-122, a Bispecific DVD-Immunoglobulin Targeting TNF- and IL-17A, in RA With Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
Genovese, M. C., Weinblatt, M. E., Aelion, J. A., Mansikka, H. T., Peloso, P. M., Chen, K., … Padley, R. J. (2018). ABT-122, a Bispecific DVD-Immunoglobulin Targeting TNF- and IL-17A, in RA With Inadequate Response to Methotrexate: A Randomized, Double-Blind Study. Arthritis & Rheumatology (Hoboken, N.J.).

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., … Pangan, A. L. (2018). Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet (London, England).

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Genovese, M. C., Weinblatt, M. E., Mease, P. J., Aelion, J. A., Peloso, P. M., Chen, K., … Leszczynski, P. (2018). Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford, England).

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
Genovese, M. C., Combe, B., Kremer, J. M., Tsai, T.-F., Behrens, F., Adams, D. H., … Nash, P. (2018). Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford, England).

Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Takeuchi, T., Genovese, M., Haraoui, B., Li, Z., Xie, L., Klar, R., … Smolen, J. (2018). Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study. JOURNAL OF RHEUMATOLOGY, 45(7), 1054.

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study
Genovese, M., Helliwell, P., Combe, B., Kremer, J., Adams, D., Lee, C., … Rahman, P. (2018). Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study. JOURNAL OF RHEUMATOLOGY, 45(7), 996.

Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Burmester, G., Fiore, S., Hu, C.-C., Fay, J., Lee, E.-B., & Genovese, M. (2018). Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 45(7), 1035.

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis
Keystone, E., Genovese, M., Smolen, J., Takeuchi, T., Hyslop, D., Macias, W., … Otawa, S. (2018). Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis. JOURNAL OF RHEUMATOLOGY, 45(7), 1003.

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin beta Receptor Fusion Protein, in Primary Sjogren's Syndrome Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial
St Clair, E. W., Baer, A. N., Wei, C., Noaiseh, G., Parke, A., Coca, A., … James, J. A. (2018). Clinical Efficacy and Safety of Baminercept, a Lymphotoxin beta Receptor Fusion Protein, in Primary Sjogren's Syndrome Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. ARTHRITIS & RHEUMATOLOGY, 70(9), 1470–80.

Patients' perceptions of unmet medical need in rheumatoid arthritis
Curtis, J., Genovese, M., Radawski, C., Hauber, B., Nowell, W. B., Hollis, K., … Cardoso, A. (2018). Patients' perceptions of unmet medical need in rheumatoid arthritis. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 27, 56.

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., … Winthrop, K. L. (2018). Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. The Journal of Rheumatology.

Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Smolen, J. S., Kang, Y. M., Yoo, W.-H., Emery, P., Weinblatt, M. E., Keystone, E. C., … Ghil, J. (2018). Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 70.

Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Burmestert, G. R., Hagino, O., Dong, Q., Stanislav, M., Gomez-Centeno, A., Selmi, C., … Genovese, M. C. (2018). Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA). ARTHRITIS & RHEUMATOLOGY, 70.

A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis
Chernoff, D., Levine, Y., Peterfy, C., & Genovese, M. C. (2018). A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 70.

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Genovese, M. C., Smolen, J. S., Takeuchi, T., Rooney, T. P., Dickson, C. L., Yang, X.-Y., … Winthrop, K. (2018). Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis. ARTHRITIS & RHEUMATOLOGY, 70.

Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Kavanaugh, A., Genovese, M. C., Winthrop, K., Creenwald, M., Ponce, L., Sosa, F. E., … Westhovens, R. (2018). Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study. ARTHRITIS & RHEUMATOLOGY, 70.

Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Genovese, M. C., Colombel, J.-F., Gellett, A. M., Xu, W., & Hardin, D. (2018). Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis. ARTHRITIS & RHEUMATOLOGY, 70.

A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Genovese, M. C., Berkowitz, M., Conaghan, P. G., Davy, K., Inman, D., Fisheleva, E., … Tak, P.-P. (2018). A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY, 70.

Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases
Postolova, A., & Genovese, M. C. (2018). Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases. ARTHRITIS & RHEUMATOLOGY, 70.

Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Fleischmann, R., Genovese, M. C., Cardoso, A., Sun, L., Chen, Y.-F., Walls, C. D., … Curtis, J. R. (2018). Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily. ARTHRITIS & RHEUMATOLOGY, 70.

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Fleischmann, R., Pangan, A. L., Mysler, E., Bessette, L., Peterfy, C., Durez, P., … Genovese, M. C. (2018). A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY, 70.

Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Pope, J. E., Quebe, A., Zhu, B., Sun, L., Gaich, C. L., de Leonardis, F., … Genovese, M. C. (2018). Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 70.

Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
Emery, P., Weinblatt, M. E., Smolen, J. S., Keystone, E. C., Genovese, M. C., Vencovsky, J., … Ghil, J. (2018). Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 70.

GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Kivitz, A. J., Mehta, D. P., Matzkies, F., Mozaffarian, A., Kunder, R., Di Paolo, J., … Genovese, M. C. (2018). GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study. ARTHRITIS & RHEUMATOLOGY. WILEY.

Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment
Genovese, M. C., van Hoogstraten, H., St John, G., Dong, Q., Jose Gomez-Reino, J., Maldonado-Cocco, J. A., … Burmester, G. R. (2018). Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment. ARTHRITIS & RHEUMATOLOGY, 70.

Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
Mease, P. J., Genovese, M. C., Weinblatt, M. E., Peloso, P. M., Chen, K., Othman, A. A., … Liu, J. (2018). Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY, 70(11), 1778–89.

Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
Peterfy, C., DiCarlo, J., Emery, P., Genovese, M. C., Keystone, E. C., Taylor, P. C., … Macias, W. (2019). Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. The Journal of Rheumatology.

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
Takeuchi, T., Genovese, M. C., Haraoui, B., Li, Z., Xie, L., Klar, R., … Smolen, J. S. (2019). Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. ANNALS OF THE RHEUMATIC DISEASES, 78(2), 171–78.

Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis.
Bay-Jensen, A. C., Platt, A., Jenkins, M. A., Weinblatt, M. E., Byrjalsen, I., Musa, K., … Karsdal, M. A. (2019). Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatology, 3, 3.

Inhibition of joint structural damage with rituximab is not dependant on clinical response in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study).
Keystone, E., Emery, P., Peterfy, C. G., Tak, P. P., Cohen, S. B., Genovese, M. C., … Shaw, T. (2006). Inhibition of joint structural damage with rituximab is not dependant on clinical response in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study). ARTHRITIS AND RHEUMATISM, 54(9), S542–S543.

Safety and efficacy of up to 9 years of etanercept therapy in North American patients with rheumatoid arthritis
Weinblatt, M., Genovese, M., Moreland, L., & Bathon, J. (2007). Safety and efficacy of up to 9 years of etanercept therapy in North American patients with rheumatoid arthritis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 56(2), AB183.

Trial of atacicept in patients with systemic lupus erythematosus (SLE).
Dall'Era, M., Chakravarty, E., Genovese, M., Wallace, D., Kavanaugh, A., Kalunian, K., … Wofsy, D. (2006). Trial of atacicept in patients with systemic lupus erythematosus (SLE). ARTHRITIS AND RHEUMATISM, 54(12), 4042–43.

Efficacy and safety of over 8 years of etanercept (Enbrel (R)) therapy in North American patients with early and long-standing rheumatoid arthritis.
Weinblatt, M. E., Genovese, M. C., Moreland, L. W., Bathon, J. M., Kremer, J. M., Fleischmann, R. M., … White, B. (2005). Efficacy and safety of over 8 years of etanercept (Enbrel (R)) therapy in North American patients with early and long-standing rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), S541.

The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (HUMIRA (R)) plus MTX or MTX alone.
Genovese, M. C., Kavanaugh, A. F., Cohen, S. B., Emery, P., Sasso, E. H., & Spencer-Green, G. T. (2005). The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (HUMIRA (R)) plus MTX or MTX alone. ARTHRITIS AND RHEUMATISM, 52(9), S451.

Integrated serum proteome analysis of autoantibodies and cytokines delineates distinct biosignatures in subsets of patients with early RA.
Hueber, W., Tomooka, B., Bruce, B., Monach, P., Fries, J. F., van Venrooij, W., … Robinson, W. H. (2005). Integrated serum proteome analysis of autoantibodies and cytokines delineates distinct biosignatures in subsets of patients with early RA. ARTHRITIS AND RHEUMATISM, 52(9), S276–S277.

Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis.
Robinson, W. H., Tomooka, B., Genovese, M. C., & Ho, P. P. (2005). Fibrinogen-induced arthritis in mice as a novel model for rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), S157.

Differential responsiveness to belimumab (BmAb) in combination with standard of care therapy in RF plus , TNF alpha-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis
Genovese, M., Filipowicz-Sosnowska, A., Merrill, J., Wasko, M., Dilorio, E., Stevenson, J., … Zilberstein, M. (2005). Differential responsiveness to belimumab (BmAb) in combination with standard of care therapy in RF plus , TNF alpha-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), S738.

Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Magloire, A., Kremer, J., Genovese, M. C., Keystone, E., Taylor, P., Zuckerman, S. H., … Macias, W. L. (2015). Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis. SWISS MEDICAL WEEKLY, 145, 4S.

Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long- Term Extension Study in Patients with Rheumatoid Arthritis
Magloire, A., Keystone, E., Taylor, P., Genovese, M., Schlichting, D., de la Torre, I., … Rooney, T. (2015). Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long- Term Extension Study in Patients with Rheumatoid Arthritis. SWISS MEDICAL WEEKLY, 145, 4S–5S.

Signal transduction blockade with imatinib mesylate prevents and treats autoimmune arthritis
Paniagua, R., Sharpe, O., Ho, P., Chan, S., Chang, A., Tomooka, B., … Robinson, W. (2007). Signal transduction blockade with imatinib mesylate prevents and treats autoimmune arthritis. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS.

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
Kremer, J. M., Schiff, M., Muram, D., Zhong, J., Alam, J., & Genovese, M. C. (2018). Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open, 4(1), e000581.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.
Kremer, J. M., Genovese, M. C., Keystone, E., Taylor, P. C., Zuckerman, S. H., Ruotolo, G., … Macias, W. L. (2017). Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, N.J.), 69(5), 943–952.

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester, G. R., Choy, E., Kivitz, A., Ogata, A., Bao, M., Nomura, A., … Genovese, M. C. (2017). Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(6), 1078–1085.

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Smolen, J. S., Kremer, J. M., Gaich, C. L., DeLozier, A. M., Schlichting, D. E., Xie, L., … Combe, B. (2017). Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Annals of the Rheumatic Diseases, 76(4), 694–700.

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.
Burmester, G. R., Landewé, R., Genovese, M. C., Friedman, A. W., Pfeifer, N. D., Varothai, N. A., & Lacerda, A. P. (2017). Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(2), 414–417.

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
Genovese, M. C., van Vollenhoven, R. F., Pacheco-Tena, C., Zhang, Y., & Kinnman, N. (2016). VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, N.J.), 68(1), 46–55.

Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.
Wilson, H. D., Mutebi, A., Revicki, D. A., Mease, P. J., Genovese, M. C., Erondu, N., … Viswanathan, H. N. (2015). Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis. Arthritis Care & Research, 67(12), 1750–6.

Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis.
Postolova, A., Troxell, M. L., Wapnir, I. L., & Genovese, M. C. (2019). Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. The Journal of Rheumatology.

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., … Winthrop, K. L. (2019). Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. JOURNAL OF RHEUMATOLOGY, 46(1), 7–18.

CLINICAL SIMILARITY OF ABP 710 WITH INFLIXIMAB (REFERENCE PRODUCT) IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Genovese, M. C., Sanchez-Burson, J., Oh, M., Balazs, E., Neal, J., Fanjiang, G., & Cohen, S. (2019). CLINICAL SIMILARITY OF ABP 710 WITH INFLIXIMAB (REFERENCE PRODUCT) IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 78, 1648–49.

FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Lee, C., Berman, A., … Genovese, M. C. (2019). FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY. ANNALS OF THE RHEUMATIC DISEASES. BMJ PUBLISHING GROUP.

UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-BEYOND STUDY
Genovese, M. C., Combe, B., Hall, S., Rubbert-Roth, A., Zhong, S., Meerwein, S., … Fleischmann, R. (2019). UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-BEYOND STUDY. ANNALS OF THE RHEUMATIC DISEASES, 78, 360–61.

SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS
Takeuchi, T., Matsubara, T., Atsumi, T., Amano, K., Ishiguro, N., Sugiyama, E., … Tanaka, Y. (2019). SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS. ANNALS OF THE RHEUMATIC DISEASES, 78, 1686–87.

SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)
Kalunian, K., Gottenberg, J.-E., Genovese, M. C., Mozaffarian, N., Bartok, B., Matzkies, F., … Walker, D. (2019). SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). ANNALS OF THE RHEUMATIC DISEASES, 78, 748–49.

GS-9876, A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY
Kivitz, A., Mehta, D., Matzkies, F., Mozaffarian, A., Kunder, R., Di Paolo, J. A., … Genovese, M. C. (2019). GS-9876, A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY. ANNALS OF THE RHEUMATIC DISEASES. BMJ PUBLISHING GROUP.

FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS
Genovese, M. C., Gaylis, N., Sikes, D., Kivitz, A., Horowitz, D. M., Peterfy, C., … Chernoff, D. (2019). FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 78, 264.

SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)
Genovese, M. C., Kalunian, K., Gottenberg, J.-E., Mozaffarian, N., Bartok, B., Matzkies, F., … Takeuchi, T. (2019). SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). ANNALS OF THE RHEUMATIC DISEASES, 78, 709–10.

HIGH UNMET NEED AMONG RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARD: REAL-WORLD ANALYSIS OF 2012-2016 US MEDICARE DATA
Dore, R. K., Antonova, J., Guo, H., Li Suying, Ozbay, B., & Genovese, M. C. (2019). HIGH UNMET NEED AMONG RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARD: REAL-WORLD ANALYSIS OF 2012-2016 US MEDICARE DATA. ANNALS OF THE RHEUMATIC DISEASES, 78, 1640.

SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
Genovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G. R., Brinker, D., Rooney, T., … Winthrop, K. (2019). SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. ANNALS OF THE RHEUMATIC DISEASES, 78, 308–9.

TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)
Dore, R. K., Antonova, J., Burudpakdee, C., Wang, X., Ozbay, B., & Genovese, M. C. (2019). TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS). ANNALS OF THE RHEUMATIC DISEASES. BMJ PUBLISHING GROUP.

PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)
Burmester, G. R., Amital, H., Rubbert-Roth, A., van Hoogstraten, H., Gervitz, L., Thangavelu, K., … Genovese, M. C. (2019). PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE). ANNALS OF THE RHEUMATIC DISEASES, 78, 1138–39.

SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS
Dore, R. K., Antonova, J., Huan, H., Gorritz, M., & Genovese, M. C. (2019). SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS. ANNALS OF THE RHEUMATIC DISEASES, 78, 700.

FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION
Gottenberg, J.-E., Genovese, M. C., Kalunian, K., Mozaffarian, N., Bartok, B., Matzkies, F., … de Vlam, K. (2019). FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION. ANNALS OF THE RHEUMATIC DISEASES, 78, 361.

INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1 YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAM
Peterfy, C., Genovese, M. C., Song, I.-H., Friedman, A., Hall, S., Mysler, E., … Strand, V. (2019). INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1 YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAM. ANNALS OF THE RHEUMATIC DISEASES, 78, 369–70.

EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES
Genovese, M. C., Burmester, G. R., Hagino, O., van Hoogstraten, H., Mangan, E., Thangavelu, K., … Mandrup-Poulsen, T. (2019). EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES. ANNALS OF THE RHEUMATIC DISEASES, 78, 1128–29.

SAFETY AND EFFICACY OF LY3337641, A BRUTON'S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY
Genovese, M. C., Spindler, A., Sagawa, A., Park, W., Dudek, A., Kivitz, A., … Nirula, A. (2019). SAFETY AND EFFICACY OF LY3337641, A BRUTON'S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY. ANNALS OF THE RHEUMATIC DISEASES, 78, 1109–10.

LONG-TERM SAFETY, IMMUNOGENICITY AND EFFICACY IN RANDOMIZED, DOUBLE-BLIND, AND OPEN-LABEL EXTENSION STUDIES COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Alten, R., Genovese, M. C., Arai, Muniz, R., & Kellner, H. (2019). LONG-TERM SAFETY, IMMUNOGENICITY AND EFFICACY IN RANDOMIZED, DOUBLE-BLIND, AND OPEN-LABEL EXTENSION STUDIES COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 78, 1135.

SYSTEMATIC ANALYSIS OF INJECTION-SITE PAIN CAUSED BY SUBCUTANEOUS ADMINISTRATION OF THE ADALIMUMAB BIOSIMILAR FKB327 VERSUS ADMINISTRATION OF THE ADALIMUMAB REFERENCE PRODUCT VIA DIFFERENT DELIVERY METHODS
Alten, R., Genovese, M. C., Boyce, M., Yonemura, T., Ito, T., & Kellner, H. (2019). SYSTEMATIC ANALYSIS OF INJECTION-SITE PAIN CAUSED BY SUBCUTANEOUS ADMINISTRATION OF THE ADALIMUMAB BIOSIMILAR FKB327 VERSUS ADMINISTRATION OF THE ADALIMUMAB REFERENCE PRODUCT VIA DIFFERENT DELIVERY METHODS. ANNALS OF THE RHEUMATIC DISEASES, 78, 699.

SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS
Genovese, M. C., Fleischmann, R., Blanco, R., Hall, S., Thomson, G., van den Bosch, F., … Song, I.-H. (2019). SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS. ANNALS OF THE RHEUMATIC DISEASES, 78, 83–84.

SAFETY AND EFFECTIVENESS OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-COMPARE STUDY
Fleischmann, R., Enejosa, J., Song, I.-H., Mysler, E., Bessette, L., Peterfy, C., … Genovese, M. C. (2019). SAFETY AND EFFECTIVENESS OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-COMPARE STUDY. ANNALS OF THE RHEUMATIC DISEASES, 78, 744–45.

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial.
Fleischmann, R., Pangan, A. L., Song, I.-H., Mysler, E., Bessette, L., Peterfy, C., … Genovese, M. C. (2019). Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial. Arthritis & Rheumatology (Hoboken, N.J.).

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
Fleischmann, R., Genovese, M. C., Lin, Y., St John, G., van der Heijde, D., Wang, S., … Burmester, G. R. (2019). Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology (Oxford, England).

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese, M. C., Kalunian, K., Gottenberg, J.-E., Mozaffarian, N., Bartok, B., Matzkies, F., … Takeuchi, T. (2019). Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA, 322(4), 315–25.

Long-Term Safety of Ixekizumab in 17034.7 Patient-Years from 15 Global Clinical Trials in Psoriasis and Psoriatic Arthritis: 3-Year Results
Combe, B., Rahman, P., Kameda, H., Canete, J., Gallo, G., Agada, N., … Janos, B. (2019). Long-Term Safety of Ixekizumab in 17034.7 Patient-Years from 15 Global Clinical Trials in Psoriasis and Psoriatic Arthritis: 3-Year Results. JOURNAL OF RHEUMATOLOGY, 46(7), 845.

Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Takeuchi, T., Genovese, M., Haraoui, B., Li, Z., Xie, L., Klar, R., … Smolen, J. (2019). Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study. JOURNAL OF RHEUMATOLOGY, 46(7), 807–8.

Assessment of Pain Relief with Baricitinib in Patients with Refractory Rheumatoid Arthritis
Pope, J., Quebe, A., Zhu, B., Sun, L., Gaich, C., De Leonardis, F., … Genovese, M. (2019). Assessment of Pain Relief with Baricitinib in Patients with Refractory Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 46(7), 807.

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Keystone, E., Genovese, M., Smolen, J., Takeuchi, T., Rooney, T., Dickson, C., … Winthrop, K. (2019). Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis. JOURNAL OF RHEUMATOLOGY, 46(7), 804–5.

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Fleischmann, R. M., Genovese, M. C., Enejosa, J. V., Mysler, E., Bessette, L., Peterfy, C., … Song, I.-H. H. (2019). Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Annals of the Rheumatic Diseases.

Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.
Radawski, C., Genovese, M. C., Hauber, B., Nowell, W. B., Hollis, K., Gaich, C. L., … Curtis, J. R. (2019). Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. Rheumatology and Therapy.

ASSESSMENT OF PAIN IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB, WHO WERE INADEQUATE RESPONDERS TO METHOTREXATE AND TUMOR NECROSIS FACTOR INHIBITORS
Taylor, P. C., Fleischmann, R., Takeuchi, T., Pope, J., Genovese, M. C., Zhu, B., … Durez, P. (2019). ASSESSMENT OF PAIN IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB, WHO WERE INADEQUATE RESPONDERS TO METHOTREXATE AND TUMOR NECROSIS FACTOR INHIBITORS. RHEUMATOLOGY, 58, 72.

SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
Walker, D., Genovese, M. C., Kalunian, K., Gottenberg, J.-E., de Vlam, K., Mozaffarian, N., … Takeuchi, T. (2019). SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS. RHEUMATOLOGY, 58.

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Genovese, M. C., Greenwald, M. W., Gutierrez-Urena, S. R., Cardiel, M. H., Poiley, J. E., Zubrzycka-Sienkiewicz, A., … Kivitz, A. J. (2019). Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. Rheumatology and Therapy.

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Peterfy, C., DiCarlo, J., Emery, P., Genovese, M. C., Keystone, E. C., Taylor, P. C., … Macias, W. (2019). MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 46(8), 887–95.

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese, M. C., van der Heijde, D., Lin, Y., St John, G., Wang, S., van Hoogstraten, H., … Burmester, G. R. (2019). Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open, 5(2), e000887.

Unique Sjogren's syndrome patient subsets defined by molecular features.
James, J. A., Guthridge, J. M., Chen, H., Lu, R., Bourn, R. L., Bean, K., … St Clair, E. W. (2019). Unique Sjogren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford, England).

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester, G. R., Strand, V., Rubbert-Roth, A., Amital, H., Raskina, T., Gomez-Centeno, A., … Genovese, M. C. (2019). Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open, 5(2), e001017.

TNF-alpha inhibition for the treatment of cardiac sarcoidosis.
Baker, M. C., Sheth, K., Witteles, R., Genovese, M. C., Shoor, S., & Simard, J. F. (2019). TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Seminars in Arthritis and Rheumatism.

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Genovese, M. C., Glover, J., Greenwald, M., Porawska, W., El Khouri, E. C., Dokoupilova, E., … Alten, R. (2019). FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research & Therapy, 21(1), 281.

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.
Smolen, J. S., Choe, J.-Y. Y., Weinblatt, M. E., Emery, P., Keystone, E., Genovese, M. C., … Ghil, J. (2020). Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 6(1).

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Combe, B., Rahman, P., Kameda, H., Canete, J. D., Gallo, G., Agada, N., … Genovese, M. C. (2020). Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Research & Therapy, 22(1), 14.

SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 6 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
Genovese, M., Smolen, J., Takeuchi, T., Rooney, T., Dickson, C., Yang, X.-Y., … Gomez, D. (2019). SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 6 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 25, S49–S50.

Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Genovese, M., Sanchez-Burson, J., Balazs, E., Everding, A., Oh, M. S., Fanjiang, G., & Cohen, S. (2019). Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components. ARTHRITIS & RHEUMATOLOGY, 71.

Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study
Cohen, S., Tuckwell, K., Kunder, R., Katsumoto, T., Zhao, R., Berman, A., … Genovese, M. (2019). Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study. ARTHRITIS & RHEUMATOLOGY. WILEY.

Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
Genovese, M., Sanchez-Burson, J., Balazs, E., Everding, A., Oh, M. S., Fanjiang, G., & Cohen, S. (2019). Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA. ARTHRITIS & RHEUMATOLOGY, 71.

Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis
Peterfy, C., Genovese, M., Song, I.-H., Friedman, A., Hall, S., Mysler, E., … Strand, V. (2019). Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71.

A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Genovese, M., de Vlam, K., Gottenberg, J.-E., Bartok, B., Tiamiyu, I., Guo, Y., … Kalunian, K. (2019). A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs. ARTHRITIS & RHEUMATOLOGY, 71.

Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Genovese, M., Kameda, H., Rahman, P., Canete, J., Garces, S., Xu, W., … Combe, B. (2019). Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials. ARTHRITIS & RHEUMATOLOGY, 71.

Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Dore, R., Antonova, J., Gorritz, M., Chang, L., He, J., & Genovese, M. (2019). Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US. ARTHRITIS & RHEUMATOLOGY, 71.

Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate-CREDO1 Study
Nasonov, E., Fatenejad, S., Korneva, E., Krechikova, D., Maslyansky, A., Plaksina, T., … Genovese, M. (2019). Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate-CREDO1 Study. ARTHRITIS & RHEUMATOLOGY, 71.

Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
Gaylis, N., Sikes, D., Kivitz, A., Horowitz, D., Peterfy, C., Levine, Y., … Genovese, M. (2019). Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator. ARTHRITIS & RHEUMATOLOGY, 71.

Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Baker, M., Sheth, K., Simard, J., Shoor, S., & Genovese, M. (2019). Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition. ARTHRITIS & RHEUMATOLOGY, 71.

Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Fleischmann, R., Enejosa, J. J., Song, I.-H., Mysler, E., Bessette, L., Peterfy, C., … Genovese, M. (2019). Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks. ARTHRITIS & RHEUMATOLOGY, 71.

Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Fleischmann, R., Genovese, M., Blanco, R., Hall, S., Thomson, G., Van den Bosch, F., … Song, I.-H. (2019). Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response. ARTHRITIS & RHEUMATOLOGY, 71.

Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Fleischmann, R., Selmi, C., Gonzalez-Gay, M. A., van Hoogstraten, H., Hagino, O., Rajput, T., … Genovese, M. (2019). Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study. ARTHRITIS & RHEUMATOLOGY, 71.

Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Dore, R., Antonova, J., Huang, H., Chang, L., Wang, X., & Genovese, M. (2019). Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US. ARTHRITIS & RHEUMATOLOGY. WILEY.

Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Genovese, M., Weinblatt, M., Wu, J., Jia, B., Quebe, A., Sun, L., … Pope, J. (2019). Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs. ARTHRITIS & RHEUMATOLOGY, 71.

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Winthrop, K., Genovese, M., Combe, B., Tanaka, Y., Kivitz, A., Matzkies, F., … Burmester, G. (2019). Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71.

Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Kavanaugh, A., Westhovens, R., Winthrop, K., Lee, S., Greer, J., DeZure, A., … Genovese, M. (2019). Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study. ARTHRITIS & RHEUMATOLOGY, 71.

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Genovese, M., Smolen, J., Takeuchi, T., Burmester, G., Brinker, D., Rooney, T., … Winthrop, K. (2019). Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis. ARTHRITIS & RHEUMATOLOGY, 71.

Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Genovese, M., Kalunian, K., Gottenberg, J.-E., Bartok, B., Tan, Y. M., Guo, Y., … Takeuchi, T. (2019). Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs. ARTHRITIS & RHEUMATOLOGY, 71.

A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Kalunian, K., Genovese, M., Gottenberg, J.-E., Bartok, B., Pechonkina, A., Guo, Y., … Takeuchi, T. (2019). A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71.

Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
van de Laar, M. A. F. J., Pope, J., Lee, Y., Fautrel, B., Ikeda, K., Quebe, A., … Taylor, P. (2019). Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71.

Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Bessette, L., Dougados, M., Mysler, E., Genovese, M., Kinch, C., Kwok, K., … van Vollenhoven, R. (2019). Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials. ARTHRITIS & RHEUMATOLOGY, 71.

Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Genovese, M., Combe, B., Hall, S., Rubbert-Roth, A., Zhong, S., Meerwein, S., … Fleischmann, R. (2019). Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks. ARTHRITIS & RHEUMATOLOGY, 71.

Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Dore, R., Antonova, J., Burudpakdee, C., Chang, L., He, J., & Genovese, M. (2019). Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US. ARTHRITIS & RHEUMATOLOGY, 71.

Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Hsu, B., Visich, J., Genovese, M., Walter, K., An, M., Laberge, R.-M., & Dananberg, J. (2019). Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA. ARTHRITIS & RHEUMATOLOGY, 71.

Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012-2016 US Medicare Data
Dore, R., Chang, L., Ji, Y., Li, S., Antonova, J., & Genovese, M. (2019). Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012-2016 US Medicare Data. ARTHRITIS & RHEUMATOLOGY, 71.

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai, M., Winthrop, K., Takeuchi, T., Hsieh, T.-Y., Chen, Y.-M., Smolen, J. S., … Genovese, M. C. (2020). Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open, 6(1).

The road to rheumatoid arthritis prevention: challenges and opportunities.
Chaichian, Y., Genovese, M. C., & Weisman, M. H. (2020). The road to rheumatoid arthritis prevention: challenges and opportunities. Clinical Rheumatology.

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
Genovese, M. C., Sanchez-Burson, J., Oh, M. S., Balazs, E., Neal, J., Everding, A., … Cohen, S. (2020). Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. Arthritis Research & Therapy, 22(1), 60.

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Galanter, J., Lee, C., … Genovese, M. C. (2020). Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). Arthritis & Rheumatology (Hoboken, N.J.).

High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis.
Boyapati, A., Schwartzman, S., Msihid, J., Choy, E., Genovese, M. C., Burmester, G. R., … Graham, N. M. (2020). High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis & Rheumatology (Hoboken, N.J.).

Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies.
Genovese, M. C., Kellner, H., Arai, Y., Muniz, R., & Alten, R. (2020). Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open, 6(1).

INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Peterfy, C. G., Genovese, M. C., Song, I.-H., Friedman, A., Hall, S., Mysler, E., … Strand, V. (2020). INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 26, 9–10.

GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING SARILUMAB: RESULTS FROM THE OPEN-LABEL EXTEND STUDY
Fleischmann, R., Selmi, C., Gonzalez-Gay, M. A., van Hoogstraten, H., Hagino, O., Rajput, T., … Genovese, M. C. (2020). GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING SARILUMAB: RESULTS FROM THE OPEN-LABEL EXTEND STUDY. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 26, 80.

A PHASE 3 CLINICAL PROGRAM OF THREE, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND COIMPARATOR-CONTROLLED STUDIES TO ASSESS THE EFFICACY AND SAFETY OF OTILIMAB IN RA: STUDY DESIGN AND METHODOLOGY
Genovese, M., Taylor, P. C., Boers, M., Strand, V., Saurigny, D., Davy, K., … Fleischmann, R. (2020). A PHASE 3 CLINICAL PROGRAM OF THREE, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND COIMPARATOR-CONTROLLED STUDIES TO ASSESS THE EFFICACY AND SAFETY OF OTILIMAB IN RA: STUDY DESIGN AND METHODOLOGY. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 26, 20.

CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS SWITCHING BETWEEN JAK1-SELECTIVE INHIBITOR UPADACITINIB AND ADALIMUMAB FOLLOWING INSUFFICIENT RESPONSE
Fleischmann, R., Genovese, M. C., Blanco, R., Hall, S., Thomson, G. T. D., Van den Bosch, F., … Song, I.-H. (2020). CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS SWITCHING BETWEEN JAK1-SELECTIVE INHIBITOR UPADACITINIB AND ADALIMUMAB FOLLOWING INSUFFICIENT RESPONSE. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 26, 68.

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese, M. C., Mysler, E., Tomita, T., Papp, K. A., Salvarani, C., Schwartzman, S., … Lebwohl, M. G. (2020). Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford, England).

POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RA
Walker, D., Winthrop, K., Genovese, M. C., Combe, B. G., Tanaka, Y., Kivitiz, A., … Burmester, G. R. (2020). POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RA. RHEUMATOLOGY, 59.

INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH MTX IN PATRIENTS WITH RA: ONE-YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAMME
Peterfy, C., Genovese, M. C., Song, I.-H., Friedman, A., Hall, S., Mysler, E., … Strand, V. (2020). INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH MTX IN PATRIENTS WITH RA: ONE-YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAMME. RHEUMATOLOGY, 59.

GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING SARILUMAB: RESULTS FROM THE OPEN LABEL EXTEND STUDY
Fleischmann, R., Selmi, C., Angel Gonzalez-Gay, M., van Hoogstraten, H., Hagino, O., Rajput, T., … Genovese, M. C. (2020). GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING SARILUMAB: RESULTS FROM THE OPEN LABEL EXTEND STUDY. RHEUMATOLOGY, 59, 108.

EFFECTS OF FILGOTINIB ON ANAEMIA, THROMBOCYTOPOENIA AND LEUKOPOENIA: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RA AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BDMARDS
Walker, D., Genovese, M. C., Kalunian, K., Gottenberg, J.-E., Bartok, B., Tan, Y. M., … Takeuchi, T. (2020). EFFECTS OF FILGOTINIB ON ANAEMIA, THROMBOCYTOPOENIA AND LEUKOPOENIA: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RA AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BDMARDS. RHEUMATOLOGY, 59, 99–100.

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Genovese, M. C., Fleischmann, R., Kivitz, A., Lee, E.-B., van Hoogstraten, H., Kimura, T., … Burmester, G. R. (2020). Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Research & Therapy, 22(1), 139.

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis
Genovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G., Brinker, D., Rooney, T. P., … Winthrop, K. L. (2020). Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. LANCET RHEUMATOLOGY, 2(6), E347–E357.

SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
Hall, S., Genovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G., Brinker, D., … Winthrop, K. L. (2020). SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. INTERNAL MEDICINE JOURNAL, 50, 16.

Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Winthrop, K. L., Harigai, M., Genovese, M. C., Lindsey, S., Takeuchi, T., Fleischmann, R., … Dougados, M. (2020). Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases.

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.
Smolen, J. S., Kang, Y. M., Yoo, W.-H. H., Emery, P., Weinblatt, M. E., Keystone, E. C., … Ghil, J. (2020). Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Research & Therapy, 22(1), 188.

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.
Alten, R., Markland, C., Boyce, M., Kawakami, K., Muniz, R., & Genovese, M. C. (2020). Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases.

Interleukin-6 receptor blockade or TNFa inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
Genovese, M. C., Burmester, G. R., Hagino, O., Thangavelu, K., Iglesias-Rodriguez, M., John, G. S., … Fleischmann, R. (2020). Interleukin-6 receptor blockade or TNFa inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research & Therapy, 22(1), 206.

Patient Disease Trajectories in Baricitinib 2-mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Genovese, M., Weinblatt, M., Wu, J., Jia, B., Quebe, A., Sun, L., … Pope, J. (2020). Patient Disease Trajectories in Baricitinib 2-mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs. JOURNAL OF RHEUMATOLOGY, 47(7), 1129.

Patient Disease Trajectories in Baricitinib-2mg-treated Patients with Rheumatoid Arthritis and Inadequate Response to csDMARDs
Pope, J., Li, Z., Genovese, M., Otawa, S., Sun, L., Chandran, S., … Dougados, M. (2020). Patient Disease Trajectories in Baricitinib-2mg-treated Patients with Rheumatoid Arthritis and Inadequate Response to csDMARDs. JOURNAL OF RHEUMATOLOGY, 47(7), 1127–28.

Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study
Genovese, M. C., Gaylis, N. B., Sikes, D., Kivitz, A., Horowitz, D. L., Peterfy, C., … Chernoff, D. (2020). Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. LANCET RHEUMATOLOGY, 2(9), E527–E538.

Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients With Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Bessette, L., Dougados, M., Mysler, E., Genovese, M., Kinch, C., Kwok, K., … van Vollenhoven, R. (2020). Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients With Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials. JOURNAL OF RHEUMATOLOGY, 47(7), 1106–7.

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Keystone, E., Winthrop, K., Genovese, M., Combe, B., Tanaka, Y., Kivitz, A., … Burmester, G. (2020). Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 47(7), 1108.

MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study
Genovese, M. C., Berkowitz, M., Conaghan, P. G., Peterfy, C., Davy, K., Fisheleva, E., … Tak, P. P. (2020). MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. LANCET RHEUMATOLOGY, 2(11), E666–E676.

Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study.
Genovese, M., Spindler, A., Sagawa, A., Park, W., Dudek, A., Kivitz, A., … Nirula, A. (2020). Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study. The Journal of Rheumatology.